

Celanese CORP  
Form 10-Q  
July 29, 2009

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 10-Q**

- þ** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**For the quarterly period ended June 30, 2009**
- o** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**(Commission File Number) 001-32410**

**CELANESE CORPORATION**  
*(Exact Name of Registrant as Specified in its Charter)*

**Delaware**  
*(State or Other Jurisdiction of  
Incorporation or Organization)*

**1601 West LBJ Freeway,  
Dallas, TX**  
*(Address of Principal Executive Offices)*

**98-0420726**  
*(I.R.S. Employer  
Identification No.)*

**75234-6034**  
*(Zip Code)*

**(972) 443-4000**  
**(Registrant's telephone number, including area code)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Edgar Filing: Celanese CORP - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of outstanding shares of the registrant's Series A common stock, \$0.0001 par value, as of July 23, 2009 was 143,579,582.

---

**CELANESE CORPORATION**

**Form 10-Q  
For the Quarterly Period Ended June 30, 2009**

**TABLE OF CONTENTS**

	<b>Page</b>
<b>PART I FINANCIAL INFORMATION</b>	
<u>Item 1.</u>	
<u>Financial Statements</u>	
<u>a) Unaudited Interim Consolidated Statements of Operations for the three and six months ended June 30, 2009 and 2008</u>	3
<u>b) Unaudited Consolidated Balance Sheets as of June 30, 2009 and December 31, 2008</u>	4
<u>c) Unaudited Interim Consolidated Statements of Shareholders' Equity and Comprehensive Income (Loss) for the six months ended June 30, 2009</u>	5
<u>d) Unaudited Interim Consolidated Statements of Cash Flows for the six months ended June 30, 2009 and 2008</u>	6
<u>e) Notes to the Unaudited Interim Consolidated Financial Statements</u>	7
<u>Item 2.</u>	
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	35
<u>Item 3.</u>	
<u>Quantitative and Qualitative Disclosures about Market Risk</u>	47
<u>Item 4.</u>	
<u>Controls and Procedures</u>	47
<b>PART II OTHER INFORMATION</b>	
<u>Item 1.</u>	
<u>Legal Proceedings</u>	48
<u>Item 1A.</u>	
<u>Risk Factors</u>	48
<u>Item 2.</u>	
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	48
<u>Item 3.</u>	
<u>Defaults Upon Senior Securities</u>	48
<u>Item 4.</u>	
<u>Submission of Matters to a Vote of Security Holders</u>	48
<u>Item 5.</u>	
<u>Other Information</u>	49
<u>Item 6.</u>	
<u>Exhibits</u>	49
<b><u>Signatures</u></b>	<b>51</b>
<u>EX-10.5</u>	
<u>EX-10.6</u>	
<u>EX-10.7</u>	
<u>EX-10.8</u>	
<u>EX-10.9</u>	
<u>EX-10.10</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-32.2</u>	
<u>EX-101 INSTANCE DOCUMENT</u>	
<u>EX-101 SCHEMA DOCUMENT</u>	
<u>EX-101 CALCULATION LINKBASE DOCUMENT</u>	
<u>EX-101 LABELS LINKBASE DOCUMENT</u>	
<u>EX-101 PRESENTATION LINKBASE DOCUMENT</u>	
<u>EX-101 DEFINITION LINKBASE DOCUMENT</u>	



**Table of Contents****Item 1. Financial Statements****CELANESE CORPORATION AND SUBSIDIARIES****UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS**

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
	<b>(In \$ millions, except for share and per share data)</b>			
Net sales	1,244	1,868	2,390	3,714
Cost of sales	(996)	(1,472)	(1,942)	(2,900)
Gross profit	248	396	448	814
Selling, general and administrative expenses	(114)	(138)	(228)	(274)
Amortization of intangible assets (primarily customer relationships)	(21)	(20)	(38)	(39)
Research and development expenses	(18)	(18)	(38)	(41)
Other (charges) gains, net	(6)	(7)	(27)	(23)
Foreign exchange gain (loss), net	1	(3)	3	4
Gain (loss) on disposition of businesses and assets, net	(1)	(3)	(4)	
Operating profit	89	207	116	441
Equity in net earnings (loss) of affiliates	27	17	25	27
Interest expense	(54)	(63)	(105)	(130)
Interest income	2	10	5	19
Dividend income cost investments	56	75	62	103
Other income (expense), net	2	1	3	5
Earnings (loss) from continuing operations before tax	122	247	106	465
Income tax (provision) benefit	(17)	(45)	(22)	(118)
Earnings (loss) from continuing operations	105	202	84	347
Earnings (loss) from operation of discontinued operations	(1)	(112)		(112)
Income tax (provision) benefit		43		43
Earnings (loss) from discontinued operations	(1)	(69)		(69)
Net earnings (loss)	104	133	84	278
Less: Net earnings (loss) attributable to noncontrolling interests		(1)		(1)

Edgar Filing: Celanese CORP - Form 10-Q

Net earnings (loss) attributable to Celanese Corporation	104	134	84	279
Cumulative preferred stock dividends	(2)	(2)	(5)	(5)
Net earnings (loss) available to common shareholders	102	132	79	274
Amounts attributable to Celanese Corporation				
Earnings (loss) from continuing operations	105	203	84	348
Earnings (loss) from discontinued operations	(1)	(69)		(69)
Net earnings (loss)	104	134	84	279
Earnings (loss) per common share basic				
Continuing operations	0.72	1.33	0.55	2.26
Discontinued operations	(0.01)	(0.46)		(0.45)
Net earnings (loss) basic	0.71	0.87	0.55	1.81
Earnings (loss) per common share diluted				
Continuing operations	0.67	1.21	0.54	2.08
Discontinued operations	(0.01)	(0.41)		(0.41)
Net earnings (loss) diluted	0.66	0.80	0.54	1.67
Weighted average shares basic	143,528,126	150,905,770	143,517,588	151,449,762
Weighted average shares diluted	157,077,970	167,814,803	156,355,049	167,561,793

See the accompanying notes to the unaudited interim consolidated financial statements.

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****UNAUDITED CONSOLIDATED BALANCE SHEETS**

	<b>As of June 30, 2009</b>	<b>As of December 31, 2008</b>
	<b>(In \$ millions, except share amounts)</b>	
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	1,145	676
Trade receivables third party and affiliates (net of allowance for doubtful accounts 2009: \$22; 2008: \$25)	702	631
Non-trade receivables	231	274
Inventories	473	577
Deferred income taxes	23	24
Marketable securities, at fair value	6	6
Assets held for sale	135	2
Other assets	63	96
Total current assets	2,778	2,286
Investments in affiliates	767	789
Property, plant and equipment (net of accumulated depreciation 2009: \$1,012; 2008: \$1,053)	2,533	2,470
Deferred income taxes	26	27
Marketable securities, at fair value	76	94
Other assets	327	357
Goodwill	788	779
Intangible assets, net	328	364
Total assets	7,623	7,166
<b>LIABILITIES AND SHAREHOLDERS EQUITY</b>		
Current liabilities		
Short-term borrowings and current installments of long-term debt third party and affiliates	224	233
Trade payables third party and affiliates	557	523
Other liabilities	529	574
Deferred income taxes	15	15
Income taxes payable	17	24
Total current liabilities	1,342	1,369



Edgar Filing: Celanese CORP - Form 10-Q

Long-term debt	3,268	3,300
Deferred income taxes	123	122
Uncertain tax positions	229	218
Benefit obligations	1,159	1,167
Other liabilities	1,254	806
Commitments and contingencies		
Shareholders' equity		
Preferred stock, \$0.01 par value, 100,000,000 shares authorized (2009 and 2008: 9,600,000 issued and outstanding)		
Series A common stock, \$0.0001 par value, 400,000,000 shares authorized (2009: 164,171,268 issued and 143,569,582 outstanding; 2008: 164,107,394 issued and 143,505,708 outstanding)		
Series B common stock, \$0.0001 par value, 100,000,000 shares authorized (2009 and 2008: 0 shares issued and outstanding)		
Treasury stock, at cost (2009 and 2008: 20,601,686 shares)	(781)	(781)
Additional paid-in capital	501	495
Retained earnings	1,114	1,047
Accumulated other comprehensive income (loss), net	(588)	(579)
Total Celanese Corporation shareholders' equity	246	182
Noncontrolling interests	2	2
Total shareholders' equity	248	184
Total liabilities and shareholders' equity	7,623	7,166

See the accompanying notes to the unaudited interim consolidated financial statements.

Table of Contents**CELANESE CORPORATION AND SUBSIDIARIES****UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF  
SHAREHOLDERS EQUITY AND COMPREHENSIVE INCOME (LOSS)**

	<b>Six Months Ended June 30, 2009</b>	
	<b>Shares Outstanding</b>	<b>Amount</b>
	<b>(In \$ millions, except share data)</b>	
Preferred stock		
Balance as of the beginning of the period	9,600,000	
Issuance of preferred stock		
Balance as of the end of the period	9,600,000	
Series A common stock		
Balance as of the beginning of the period	143,505,708	
Stock option exercises	41,101	
Purchases of treasury stock, including related fees		
Stock awards	22,773	
Balance as of the end of the period	143,569,582	
Treasury stock		
Balance as of the beginning of the period	20,601,686	(781)
Purchases of treasury stock, including related fees		
Balance as of the end of the period	20,601,686	(781)
Additional paid-in capital		
Balance as of the beginning of the period		495
Stock-based compensation, net of tax		5
Stock option exercises		1
Balance as of the end of the period		501
Retained earnings		
Balance as of the beginning of the period		1,047
Net earnings (loss) attributable to Celanese Corporation		84
Series A common stock dividends		(12)
Preferred stock dividends		(5)
Balance as of the end of the period		1,114
Accumulated other comprehensive income (loss), net		
Balance as of the beginning of the period		(579)

Edgar Filing: Celanese CORP - Form 10-Q

Unrealized gain (loss) on securities	(13)
Foreign currency translation	(9)
Unrealized gain (loss) on interest rate swaps	14
Pension and postretirement benefits	(1)
Balance as of the end of the period	(588)
Total Celanese Corporation shareholders' equity	246
Noncontrolling interests	
Balance as of the beginning of the period	2
Net earnings (loss) attributable to noncontrolling interests	
Balance as of the end of the period	2
Total shareholders' equity	248
Comprehensive income (loss)	
Net earnings (loss)	84
Other comprehensive income (loss), net of tax:	
Unrealized gain (loss) on securities	(13)
Foreign currency translation	(9)
Unrealized gain (loss) on interest rate swaps	14
Pension and postretirement benefits	(1)
Total comprehensive income (loss), net of tax	75
Comprehensive income (loss) attributable to noncontrolling interests	
Comprehensive income (loss) attributable to Celanese Corporation	75

See the accompanying notes to the unaudited interim consolidated financial statements.

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**

	<b>Six Months Ended</b>	
	<b>June 30,</b>	
	<b>2009</b>	<b>2008</b>
	<b>(In \$ millions)</b>	
Operating activities		
Net earnings (loss)	84	278
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:		
Other charges (gains), net of amounts used	(6)	5
Depreciation, amortization and accretion	156	178
Deferred income taxes, net	3	(8)
(Gain) loss on disposition of businesses and assets, net	3	(2)
Other, net	12	32
Operating cash provided by (used in) discontinued operations	1	5
Value-added tax on deferred proceeds from Ticona Kelsterbach plant relocation		59
Changes in operating assets and liabilities:		
Trade receivables third party and affiliates, net	(70)	(14)
Inventories	75	(94)
Other assets	55	(1)
Trade payables third party and affiliates	35	6
Other liabilities	(49)	(98)
Net cash provided by operating activities	299	346
Investing activities		
Capital expenditures on property, plant and equipment	(96)	(136)
Acquisitions and related fees, net of cash acquired		(1)
Proceeds from sale of businesses and assets, net	(1)	3
Deferred proceeds on Ticona Kelsterbach plant relocation	412	311
Capital expenditures related to Ticona Kelsterbach plant relocation	(147)	(62)
Proceeds from sale of marketable securities	15	96
Purchases of marketable securities		(83)
Settlement of cross currency swap agreement		(93)
Other, net		(68)
Net cash provided by (used in) investing activities	183	(33)
Financing activities		
Short-term borrowings (repayments), net	6	(47)
Proceeds from long-term debt		13
Repayments of long-term debt	(46)	(23)
Refinancing costs	(3)	
Purchases of treasury stock, including related fees		(126)
Stock option exercises	1	17
Series A common stock dividends	(12)	(12)

Edgar Filing: Celanese CORP - Form 10-Q

Preferred stock dividends	(5)	(5)
Net cash used in financing activities	(59)	(183)
Exchange rate effects on cash and cash equivalents	46	28
Net increase (decrease) in cash and cash equivalents	469	158
Cash and cash equivalents at beginning of period	676	825
Cash and cash equivalents at end of period	1,145	983

See the accompanying notes to the unaudited interim consolidated financial statements.

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

**1. Description of the Company and Basis of Presentation**

***Description of the Company***

Celanese Corporation and its subsidiaries (collectively the Company) is a leading global integrated chemical and advanced materials company. The Company's business involves processing chemical raw materials, such as methanol, carbon monoxide and ethylene, and natural products, including wood pulp, into value-added chemicals, thermoplastic polymers and other chemical-based products.

***Basis of Presentation***

The unaudited interim consolidated financial statements for the three and six months ended June 30, 2009 and 2008 contained in this Quarterly Report were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) for all periods presented. The unaudited interim consolidated financial statements and other financial information included in this Quarterly Report, unless otherwise specified, have been presented to separately show the effects of discontinued operations.

In the opinion of management, the accompanying unaudited consolidated balance sheets and related unaudited interim consolidated statements of operations, cash flows and shareholders' equity and comprehensive income (loss) include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with US GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission (SEC). These unaudited interim consolidated financial statements should be read in conjunction with the Celanese Corporation and Subsidiaries consolidated financial statements as of and for the year ended December 31, 2008, as filed on February 13, 2009 with the SEC as part of the Company's Annual Report on Form 10-K (the 2008 Form 10-K).

Operating results for the three and six months ended June 30, 2009 and 2008 are not necessarily indicative of the results to be expected for the entire year.

***Estimates and Assumptions***

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues, expenses and allocated charges during the reporting period. Significant estimates pertain to impairments of goodwill, intangible assets and other long-lived assets, purchase price allocations, restructuring costs and other (charges) gains, net, income taxes, pension and other postretirement benefits, asset retirement obligations, environmental liabilities and loss contingencies, among others. Actual results could differ from those estimates.

***Reclassifications***

The Company has reclassified certain prior period amounts to conform to the current period's presentation.

**2. Recent Accounting Pronouncements**

In December 2008, the Financial Accounting Standards Board ( FASB ) issued FASB Staff Position ( FSP ) No. FAS 132(R)-1, *Employers' Disclosures about Postretirement Benefit Plan Assets*, ( FSP No. FAS 132(R)-1 ). FSP No. FAS 132(R)-1 requires enhanced disclosures about the plan assets of a Company's defined benefit pension and other postretirement plans intended to provide financial statement users with a greater understanding of: 1) how investment allocation decisions are made; 2) the major categories of plan assets; 3) the inputs and valuation techniques used to measure the fair value of plan assets; 4) the effect of fair value measurements using significant unobservable inputs on changes in plan assets for the period; and 5) significant concentrations of risk within plan

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

assets. The Company adopted FSP FAS No. FAS 132(R)-1 beginning January 1, 2009. This FSP had no impact on the Company's financial position, results of operations or cash flows.

In April 2009, the FASB issued FSP No. FAS 141(R)-1, *Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies*, ( FSP No. FAS 141(R)-1 ). FSP No. FAS 141(R)-1 amends FASB Statement No. 141(R), *Business Combinations*, to address application issues related to the measurement, accounting and disclosure of assets and liabilities arising from contingencies in a business combination. The Company adopted FSP FAS No. 141(R)-1 upon issuance. This FSP had no impact on the Company's financial position, results of operations or cash flows.

In April 2009, the FASB issued FSP No. FAS 157-4, *Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly*, ( FSP No. FAS 157-4 ). FSP No. FAS 157-4 provides additional guidance for estimating fair value in accordance with FASB Statement No. 157, *Fair Value Measurements* ( SFAS No. 157 ), and emphasizes that even if there has been a significant decrease in the volume and level of activity for the asset or liability and regardless of the valuation technique(s) used, the objective of a fair value measurement remains the same. The Company adopted FSP FAS No. 157-4 beginning April 1, 2009. This FSP had no material impact on the Company's financial position, results of operations or cash flows.

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments*, ( FSP No. FAS 107-1 and APB 28-1 ). FSP No. FAS 107-1 and APB 28-1 amends FASB Statement No. 107, *Disclosures about Fair Value of Financial Instruments*, to require disclosures about fair value of financial instruments for interim reporting periods of publicly traded companies as well as in annual financial statements and also amends Accounting Principles Board Opinion No. 28, *Interim Financial Reporting*, to require those disclosures in summarized financial information at interim reporting periods. The Company adopted FSP FAS No. 107-1 and APB 28-1 beginning April 1, 2009. This FSP had no impact on the Company's financial position, results of operations or cash flows.

In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2, *Recognition and Presentation of Other-Than-Temporary Impairments*, ( FSP No. FAS 115-2 and FAS 124-2 ). FSP No. FAS 115-2 and FAS 124-2 provides guidance to determine whether the holder of an investment in a debt security for which changes in fair value are not regularly recognized in earnings should recognize a loss in earnings when the investment is impaired. This FSP also improves the presentation and disclosure of other-than-temporary impairments on debt and equity securities in the consolidated financial statements. The Company adopted FSP FAS No. 115-2 and FAS 124-2 beginning April 1, 2009. This FSP had no material impact on the Company's financial position, results of operations or cash flows.

In May 2009, the FASB issued Statement of Financial Accounting Standards ( SFAS ) No. 165, *Subsequent Events* ( SFAS No. 165 ) to establish accounting and disclosure standards for events that occur after the balance sheet date but before financial statements are issued or are available to be issued. It defines financial statements as available to be issued, requiring the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date, whether it be the date the financial statements were issued or the date they were available to be issued. The Company adopted SFAS No. 165 upon issuance. This standard had no material impact on the Company's financial



position, results of operations or cash flows.

In June 2009, the FASB issued SFAS No. 168, *The FASB Accounting Standards Codification<sup>TM</sup> and the Hierarchy of Generally Accepted Accounting Principles*, ( SFAS No. 168 ), which becomes effective for financial statements issued for interim and annual periods ending after September 15, 2009. SFAS No. 168 replaces SFAS No. 162, *The Hierarchy of Generally Accepted Accounting Principles*. SFAS No. 168 identifies the sources of accounting principles and the framework for selecting principles used in the preparation of financial statements of

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

nongovernmental entities that are presented in conformity with US GAAP (the GAAP hierarchy). This standard will have no impact on the Company's financial position, results of operations or cash flows.

**3. Asset Sales**

In July 2007, the Company reached an agreement with Babcock & Brown, a worldwide investment firm which specializes in real estate and utilities development, to sell the Company's Pampa, Texas, facility. The Company ceased its chemical operations at the site in December 2008. Proceeds received upon certain milestone events are treated as deferred proceeds and included in noncurrent Other liabilities in the Company's unaudited consolidated balance sheets until the transaction is complete (expected to be in 2010), as defined in the sales agreement. These operations are included in the Company's Acetyl Intermediates segment.

At June 30, 2009 and December 31, 2008, Assets held for sale included an office building with a net book value of \$2 million.

**4. Inventories**

	<b>As of June 30, 2009</b>	<b>As of December 31, 2008</b>
	<b>(In \$ millions)</b>	
Finished goods	342	434
Work-in-process	24	24
Raw materials and supplies	107	119
Total	473	577

**5. Marketable Securities, at Fair Value**

The Company's captive insurance companies and pension-related trusts hold available-for-sale securities for capitalization and funding requirements, respectively. The Company received proceeds from sales of marketable securities and recorded realized gains (losses) to Other income (expense), net in the consolidated statements of operations as follows:

	<b>Three Months Ended June 30, 2009</b>		<b>Six Months Ended June 30, 2008</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>

	<b>(In \$ millions)</b>			
Proceeds from sale of securities		33	15	96
Realized gain on sale of securities	1	2	3	2
Realized loss on sale of securities		(1)		(3)
Net realized gain (loss) on sale of securities	1	1	3	(1)

The Company reviews all investments for other-than-temporary impairment at least quarterly or as indicators of impairment exist. Indicators of impairment include the duration and severity of the decline in fair value below carrying value as well as the intent and ability to hold the investment to allow for a recovery in the market value of the investment. In addition, the Company considers qualitative factors that include, but are not limited to: (i) the financial condition and business plans of the investee including its future earnings potential, (ii) the investee's credit rating, and (iii) the current and expected market and industry conditions in which the investee operates. If a decline in the fair value of an investment is deemed by management to be other-than-temporary, the Company writes down

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

the carrying value of the investment to fair value, and the amount of the write-down is included in net earnings. Such a determination is dependent on the facts and circumstances relating to each investment. No investments were determined to be other-than-temporarily impaired for the six months ended June 30, 2009. All securities in an unrealized loss position have been in a loss position for less than twelve months.

The amortized cost, gross unrealized gain, gross unrealized loss and fair values for available-for-sale securities by major security type were as follows:

	<b>Amortized Cost</b>	<b>Gross Unrealized Gain (In \$ millions)</b>	<b>Gross Unrealized Loss</b>	<b>Fair Value</b>
Debt securities				
US government	29	4		33
US corporate	1			1
Total debt securities	30	4		34
Equity securities	56		(13)	43
Money market deposits and other securities	5			5
As of June 30, 2009	91	4	(13)	82
Debt securities				
US government	35	17		52
US corporate	3			3
Total debt securities	38	17		55
Equity securities	55		(13)	42
Money market deposits and other securities	3			3
As of December 31, 2008	96	17	(13)	100

Fixed maturities as of June 30, 2009 by contractual maturity are shown below. Actual maturities could differ from contractual maturities because borrowers may have the right to call or prepay obligations, with or without call or prepayment penalties.

**Amortized  
Cost  
(In \$ millions)**      **Fair  
Value**

Within one year	6	6
From one to five years		
From six to ten years		
Greater than ten years	29	33
Total	35	39

Proceeds received from fixed maturities that mature within one year are expected to be reinvested into additional securities upon such maturity.

Table of Contents

## CELANESE CORPORATION AND SUBSIDIARIES

NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)

## 6. Goodwill and Intangible Assets, Net

*Goodwill*

	Advanced Engineered Materials	Consumer Specialties	Industrial Specialties	Acetyl Intermediates	Other	Total
	(In \$ millions)					
As of December 31, 2008	258	252	34	235		779
Exchange rate changes	2	4		3		9
As of June 30, 2009	260	256	34	238		788

*Intangible Assets, Net*

	Trademarks and Trade names	Licenses	Customer-Related Intangible Assets	Developed Technology	Other	Total
	(In \$ millions)					
Gross Asset Value						
As of December 31, 2008	82	29	537	12	12	672
Exchange rate changes			7			7
As of June 30, 2009	82	29	544	12	12	679
Accumulated Amortization						
As of December 31, 2008		(3)	(285)	(10)	(10)	(308)
Amortization	(3)	(1)	(33)		(1)	(38)
Exchange rate changes			(5)			(5)
As of June 30, 2009	(3)	(4)	(323)	(10)	(11)	(351)
Net book value as of June 30, 2009	79	25	221	2	1	328

Edgar Filing: Celanese CORP - Form 10-Q

Aggregate amortization expense for intangible assets with finite lives during the three months ended June 30, 2009 and 2008 was \$21 million and \$20 million, respectively. Aggregate amortization expense for intangible assets with finite lives during the six months ended June 30, 2009 and 2008 was \$38 million and \$39 million, respectively.

During the three months ended June 30, 2009 the Company accelerated amortization on the AT Plastics trade name which will be discontinued August 1, 2009. The remaining net book value (\$3 million) of the AT Plastics trade name will be amortized through July 31, 2009.

Estimated amortization expense for the succeeding five fiscal years is \$64 million in 2010, \$59 million in 2011, \$45 million in 2012, \$29 million in 2013 and \$19 million in 2014.

For the three and six months ended June 30, 2009, the Company did not renew or extend any intangible assets.

Table of Contents**CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)****7. Debt**

	<b>As of June 30, 2009</b>	<b>As of December 31, 2008</b>
	<b>(In \$ millions)</b>	
Short-term borrowings and current installments of long-term debt third party and affiliates		
Current installments of long-term debt	72	81
Short-term borrowings, principally comprised of amounts due to affiliates	152	152
Total	224	233
Long-term debt		
Senior credit facilities: Term loan facility due 2014	2,789	2,794
Term notes 7.125%, due 2009		14
Pollution control and industrial revenue bonds, interest rates ranging from 5.7% to 6.7%, due at various dates through 2030	181	181
Obligations under capital leases and other secured and unsecured borrowings due at various dates through 2054	203	211
Other bank obligations, interest rates ranging from 3.0% to 5.3%, due at various dates through 2014	167	181
Subtotal	3,340	3,381
Less: Current installments of long-term debt	72	81
Total	3,268	3,300

***Senior Credit Facilities***

The Company's senior credit agreement consists of \$2,280 million of US dollar-denominated and 400 million of Euro-denominated term loans due 2014, a \$600 million revolving credit facility terminating in 2013 and a \$228 million credit-linked revolving facility terminating in 2014. Borrowings under the senior credit agreement bear interest at a variable interest rate based on LIBOR (for US dollars) or EURIBOR (for Euros), as applicable, or, for US dollar-denominated loans under certain circumstances, a base rate, in each case plus an applicable margin. The applicable margin for the term loans and any loans under the credit-linked revolving facility is 1.75%, subject to potential reductions as defined in the senior credit agreement. As of June 30, 2009 the applicable margin was 1.75%. The term loans under the senior credit agreement are subject to amortization at 1% of the initial principal amount per annum, payable quarterly. The remaining principal amount of the term loans is due on April 2, 2014.



As of June 30, 2009, there were \$89 million of letters of credit issued under the credit-linked revolving facility and \$139 million remained available for borrowing. As of June 30, 2009, there were no outstanding borrowings or letters of credit issued under the revolving credit facility.

On June 30, 2009, the Company entered into an amendment to the senior credit agreement. The amendment reduced the amount available under the revolving credit portion of the senior credit agreement from \$650 million to \$600 million and increased the first lien senior secured leverage ratio covenant that is applicable when any amount is outstanding under the revolving credit portion of the senior credit agreement as set forth below. Prior to giving

Table of Contents**CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

effect to the amendment, the maximum first lien senior secured leverage ratio was 3.90 to 1.00. As amended, the maximum senior secured leverage ratio for the following trailing four-quarter periods is as follows:

	<b>First Lien Senior Secured Leverage Ratio</b>
June 30, 2009	4.75 to 1.00
September 30, 2009	5.75 to 1.00
December 31, 2009	5.25 to 1.00
March 31, 2010	4.75 to 1.00
June 30, 2010	4.25 to 1.00
September 30, 2010	4.25 to 1.00
December 31, 2010 and thereafter	3.90 to 1.00

As a condition to borrowing funds or requesting that letters of credit be issued under that facility, the Company's first lien senior secured leverage ratio (as calculated as of the last day of the most recent fiscal quarter for which financial statements have been delivered under the revolving facility) cannot exceed a certain threshold as specified above. The first lien senior secured leverage ratio is calculated as the ratio of consolidated first lien senior secured debt to earnings before interest, taxes, depreciation and amortization, subject to adjustment identified in the credit agreement.

Based on the estimated first lien senior secured leverage ratio for the trailing four quarters at June 30, 2009, the Company's borrowing capacity under the revolving credit facility is currently \$600 million. Further, the Company's first lien senior secured leverage ratio must be maintained at or below that threshold while any amounts are outstanding under the revolving credit facility. As of the quarter ended June 30, 2009, the Company estimates its first lien senior secured leverage ratio to be 3.80 to 1.00 (which would be 4.59 to 1.00 were the revolving credit facility fully drawn). The maximum first lien senior secured leverage ratio under the revolving credit facility for such quarter is 4.75 to 1.00.

The Company's senior credit agreement also contains a number of restrictions on certain of its subsidiaries, including, but not limited to, restrictions on their ability to incur indebtedness; grant liens on assets; merge, consolidate, or sell assets; pay dividends or make other restricted payments; make investments; prepay or modify certain indebtedness; engage in transactions with affiliates; enter into sale-leaseback transactions or hedge transactions; or engage in other businesses. The senior credit agreement also contains a number of affirmative covenants and events of default, including a cross default to other debt of certain of the Company's subsidiaries in an aggregate amount equal to more than \$40 million and the occurrence of a change of control. Failure to comply with these covenants, or the occurrence of any other event of default, could result in acceleration of the loans and other financial obligations under the Company's senior credit agreement.

The senior credit agreement is guaranteed by Celanese Holdings LLC, a subsidiary of Celanese Corporation, and certain domestic subsidiaries of the Company's subsidiary, Celanese US Holdings LLC ( "Celanese US" ), a Delaware limited liability company, and is secured by a lien on substantially all assets of Celanese US and such subsidiaries,

Edgar Filing: Celanese CORP - Form 10-Q

subject to certain agreed exceptions, pursuant to the Guarantee and Collateral Agreement, dated as of April 2, 2007, by and among Celanese Holdings LLC, Celanese US, certain subsidiaries of Celanese US and Deutsche Bank AG, New York Branch, as Administrative Agent and as Collateral Agent.

The Company is in compliance with all of the covenants related to its debt agreements as of June 30, 2009.

Table of Contents**CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)****8. Other Liabilities**

The components of current Other liabilities are as follows:

	<b>As of June 30, 2009</b>	<b>As of December 31, 2008</b>
	<b>(In \$ millions)</b>	
Salaries and benefits	92	107
Environmental	17	19
Restructuring	25	32
Insurance	33	34
Asset retirement obligations	8	9
Derivatives	79	67
Current portion of benefit obligations	61	57
Interest	26	54
Sales and use tax/foreign withholding tax payable	11	16
Uncertain tax positions	5	
Other	172	179
<b>Total</b>	<b>529</b>	<b>574</b>

The components of noncurrent Other liabilities are as follows:

	<b>As of June 30, 2009</b>	<b>As of June 30, 2008</b>
	<b>(In \$ millions)</b>	
Environmental	84	79
Insurance	93	85
Deferred revenue	52	56
Deferred proceeds (see Notes 3 and 19)	830	370
Asset retirement obligations	37	40
Derivatives	54	76
Other	104	100
<b>Total</b>	<b>1,254</b>	<b>806</b>



**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)****9. Benefit Obligations**

The components of net periodic benefit costs recognized are as follows:

	Pension		Postretirement		Pension		Postretirement	
	Benefits		Benefits		Benefits		Benefits	
	Three Months Ended June 30,		Six Months Ended June 30,		Six Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008	2009	2008	2009	2008
	(In \$ millions)							
Service cost	7	9	1	1	14	16	1	1
Interest cost	48	57	4	5	95	99	8	9
Expected return on plan assets	(52)	(64)			(102)	(111)		
Recognized actuarial (gain) loss	1		(2)	(1)	1		(3)	(2)
Settlement (gain) loss	1				1			
Total	5	2	3	5	9	4	6	8

The Company expects to contribute \$40 million to its defined benefit pension plans in 2009. As of June 30, 2009, \$19 million of contributions have been made. The Company's estimates of its US defined benefit pension plan contributions reflect the provisions of the Pension Funding Equity Act of 2004 and the Pension Protection Act of 2006.

The Company expects to make benefit payments of \$35 million under the provisions of its other postretirement benefit plans in 2009. As of June 30, 2009, \$14 million of benefit payments have been made.

The Company participates in multiemployer defined benefit plans in Europe covering certain employees. The Company's contributions to the multiemployer defined benefit plans are based on specified percentages of employee contributions and totaled \$4 million for the six months ended June 30, 2009.

**10. Environmental*****General***

The Company is subject to environmental laws and regulations worldwide which impose limitations on the discharge of pollutants into the air and water and establish standards for the treatment, storage and disposal of solid and hazardous wastes. The Company believes that it is in substantial compliance with all applicable environmental laws and regulations. The Company is also subject to retained environmental obligations specified in various contractual agreements arising from divestiture of certain businesses by the Company or one of its predecessor companies. The

Company's environmental reserves for remediation matters were \$101 million and \$98 million as of June 30, 2009 and December 31, 2008, respectively.

***Remediation***

Due to its industrial history and through retained contractual and legal obligations, the Company has the obligation to remediate specific areas on its own sites as well as on divested, orphan or US Superfund sites (as defined below). In addition, as part of the demerger agreement between the Company and Hoechst AG (Hoechst), a specified portion of the responsibility for environmental liabilities from a number of Hoechst divestitures was transferred to the Company. The Company provides for such obligations when the event of loss is probable and reasonably estimable. The Company believes that environmental remediation costs will not have a material adverse effect on the financial position of the Company, but may have a material adverse effect on the results of operations or cash flows in any given accounting period.

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

***US Superfund Sites***

In the US, the Company may be subject to substantial claims brought by US federal or state regulatory agencies or private individuals pursuant to statutory authority or common law. In particular, the Company has a potential liability under the US Federal Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, and related state laws (collectively referred to as Superfund ) for investigation and cleanup costs at approximately 50 sites. At most of these sites, numerous companies, including certain companies comprising the Company, or one of its predecessor companies, have been notified that the Environmental Protection Agency, state governing bodies or private individuals consider such companies to be potentially responsible parties ( PRP ) under Superfund or related laws. The proceedings relating to these sites are in various stages. The cleanup process has not been completed at most sites and the status of the insurance coverage for most of these proceedings is uncertain. Consequently, the Company cannot determine accurately its ultimate liability for investigation or cleanup costs at these sites.

As events progress at each site for which it has been named a PRP, the Company accrues, as appropriate, a liability for site cleanup. Such liabilities include all costs that are probable and can be reasonably estimated. In establishing these liabilities, the Company considers its shipment of waste to a site, its percentage of total waste shipped to the site, the types of wastes involved, the conclusions of any studies, the magnitude of any remedial actions that may be necessary and the number and viability of other PRPs. Often the Company joins with other PRPs to sign joint defense agreements that settle, among PRPs, each party s percentage allocation of costs at the site. Although the ultimate liability may differ from the estimate, the Company routinely reviews the liabilities and revises the estimate, as appropriate, based on the most current information available. The Company had provisions totaling \$11 million for both June 30, 2009 and December 31, 2008 for US Superfund sites.

Additional information relating to environmental remediation activity is contained in the footnotes to the Company s consolidated financial statements included in the 2008 Form 10-K.

**11. Shareholders Equity**

***Treasury Stock***

In February 2008, the Company s Board of Directors authorized the repurchase of up to \$400 million of the Company s Series A common stock. This authorization was increased to \$500 million in October 2008. The authorization gives management discretion in determining the conditions under which shares may be repurchased. As of June 30, 2009, the Company had repurchased 9,763,200 shares of its Series A common stock pursuant to this authorization. During the six months ended June 30, 2009, the Company did not repurchase any shares of its Series A common stock. During the six months ended June 30, 2008, the Company repurchased 2,948,900 shares of its Series A common stock at an average purchase price of \$42.71 per share.

Purchases of treasury stock reduce the number of shares outstanding and the repurchased shares may be used by the Company for compensation programs utilizing the Company s stock and other corporate purposes. The Company accounts for treasury stock using the cost method and includes treasury stock as a component of Shareholders equity.

***Other Comprehensive Income (Loss), Net***



Adjustments to net earnings (loss) to calculate other comprehensive income (loss) totaled \$(9) million and \$9 million for the six months ended June 30, 2009 and 2008, respectively. These amounts were net of tax benefit of \$1 million and \$0 million for the six months ended June 30, 2009 and 2008, respectively. Adjustments to net earnings (loss) for comprehensive income (loss) totaled \$102 million and \$42 million for the three months ended June 30, 2009 and 2008, respectively. These amounts were net of tax benefit of \$1 million and \$0 million for the three months ended June 30, 2009 and 2008, respectively.

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

**12. Commitments and Contingencies**

The Company is involved in a number of legal proceedings, lawsuits and claims incidental to the normal conduct of business, relating to such matters as product liability, antitrust, past waste disposal practices and release of chemicals into the environment. While it is impossible at this time to determine with certainty the ultimate outcome of these proceedings, lawsuits and claims, the Company is actively defending those matters where the Company is named as a defendant. Additionally, the Company believes it has determined its best estimate, based on the advice of legal counsel, that adequate reserves have been made and that the ultimate outcomes will not have a material adverse effect on the financial position of the Company; however, the ultimate outcome of any given matter may have a material impact on the results of operations or cash flows of the Company in any given reporting period.

***Plumbing Actions***

CNA Holdings, LLC ( CNA Holdings ), a US subsidiary of the Company, which included the US business now conducted by the Ticona business included in the Advanced Engineered Materials segment, along with Shell Oil Company ( Shell ), E.I. DuPont de Nemours and Company ( DuPont ) and others, has been a defendant in a series of lawsuits, including a number of class actions, alleging that plastics manufactured by these companies that were utilized in the production of plumbing systems for residential property were defective or caused such plumbing systems to fail. Based on, among other things, the findings of outside experts and the successful use of Ticona s acetal copolymer in similar applications, CNA Holdings does not believe Ticona s acetal copolymer was defective or caused the plumbing systems to fail. In many cases CNA Holdings potential future exposure may be limited by invocation of the statute of limitations since CNA Holdings ceased selling the resin for use in the plumbing systems in site-built homes during 1986 and in manufactured homes during 1990.

In November 1995, CNA Holdings, DuPont and Shell entered into national class action settlements which called for the replacement of plumbing systems of claimants who have had qualifying leaks, as well as reimbursements for certain leak damage. In connection with such settlements, the three companies had agreed to fund these replacements and reimbursements up to an aggregate amount of \$950 million. In 2002, based on projections that the cap would be exceeded, Shell and the Company added \$75 million for a total of \$1.025 billion. The cap was further increased by \$78 million to \$1.103 billion primarily as a result of funds transferred from the US Brass Trust. Additional funds transferred from the US Brass Trust may further increase the cap in the future. Excess funds remaining upon complete dissolution of the class action are payable to Shell and the Company.

During the period between 1995 and 2001, CNA Holdings was also named as a defendant in the following putative class actions:

*Cox, et al. v. Hoechst Celanese Corporation, et al.*, No. 94-0047 (Chancery Ct., Obion County, Tennessee) (class was certified).

*Couture, et al. v. Shell Oil Company, et al.*, No. 200-06-000001-985 (Quebec Superior Court, Canada).

*Dilday, et al. v. Hoechst Celanese Corporation, et al.*, No. 15187 (Chancery Ct., Weakley County, Tennessee).

*Furlan v. Shell Oil Company, et al.*, No. C967239 (British Columbia Supreme Court, Vancouver Registry, Canada).

*Gariepy, et al. v. Shell Oil Company, et al.*, No. 30781/99 (Ontario Court General Division, Canada).

*Shelter General Insurance Co., et al. v. Shell Oil Company, et al.*, No. 16809 (Chancery Ct., Weakley County, Tennessee).

*St. Croix Ltd., et al. v. Shell Oil Company, et al.*, No. 1997/467 (Territorial Ct., St. Croix Division, the US Virgin Islands).

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

*Tranter v. Shell Oil Company, et al.*, No. 46565/97 (Ontario Court General Division, Canada).

In addition, between 1994 and 2008 CNA Holdings was named as a defendant in numerous non-class actions filed in Florida, Georgia, Louisiana, Mississippi, New Jersey, Tennessee and Texas, the US Virgin Islands and Canada of which nine are currently pending. In all of these actions, the plaintiffs have sought recovery for alleged damages caused by leaking polybutylene plumbing. Damage amounts have generally not been specified but these cases generally do not involve (either individually or in the aggregate) a large number of homes.

As of June 30, 2009 and December 31, 2008, the Company had remaining accruals of \$62 million and \$64 million, respectively, of which \$2 million is included in current Other liabilities in the unaudited consolidated balance sheets.

The Company reached settlements with CNA Holdings insurers specifying their responsibility for these claims. During the year ended December 31, 2007, the Company received \$23 million of insurance proceeds from various CNA Holdings insurers as full satisfaction for their responsibility for these claims. During the year ended December 31, 2008, the Company received less than \$1 million from insurers. During the six months ended June 30, 2009, the Company recognized a \$2 million decrease in legal reserves for plumbing claims for which the statute of limitations has expired and received \$1 million of insurance recoveries associated with plumbing cases.

***Plumbing Insurance Indemnifications***

Celanese GmbH entered into agreements with insurance companies related to product liability settlements associated with Celcon® plumbing claims. These agreements, except those with insolvent insurance companies, require the Company to indemnify and/or defend these insurance companies in the event that third parties seek additional monies for matters released in these agreements. The indemnifications in these agreements do not provide for time limitations.

In certain of the agreements, Celanese GmbH received a fixed settlement amount. The indemnities under these agreements generally are limited to, but in some cases are greater than, the amount received in settlement from the insurance company. The maximum exposure under these indemnifications is \$95 million. Other settlement agreements have no stated limits.

There are other agreements whereby the settling insurer agreed to pay a fixed percentage of claims that relate to that insurer's policies. The Company has provided indemnifications to the insurers for amounts paid in excess of the settlement percentage. These indemnifications do not provide for monetary or time limitations.

***Sorbates Antitrust Actions***

In May 2002, the European Commission informed Hoechst of its intent to officially investigate the sorbates industry. In early January 2003, the European Commission served Hoechst, Nutrinova, Inc., a US subsidiary of Nutrinova Nutrition Specialties & Food Ingredients GmbH and previously a wholly owned subsidiary of Hoechst ( Nutrinova ), and a number of competitors of Nutrinova with a statement of objections alleging unlawful, anticompetitive behavior affecting the European sorbates market. In October 2003, the European Commission ruled that Hoechst, Chisso Corporation, Daicel Chemical Industries Ltd. ( Daicel ), The Nippon Synthetic Chemical Industry Co. Ltd. and Ueno

Fine Chemicals Industry Ltd. operated a cartel in the European sorbates market between 1979 and 1996. The European Commission imposed a total fine of 138 million on such companies, of which 99 million was assessed against Hoechst and its legal successors. The case against Nutrinova was closed. Pursuant to the Demerger Agreement with Hoechst, Celanese GmbH was assigned the obligation related to the sorbates antitrust matter; however, Hoechst, and its legal successors, agreed to indemnify Celanese GmbH for 80% of any costs Celanese GmbH incurred relative to this matter. Accordingly, Celanese GmbH recognized a receivable from Hoechst from this indemnification. In June 2008, the Court of First Instance of the European Communities (Fifth Chamber) reduced the fine against Hoechst to 74.25 million and in July 2008, Hoechst paid the 74.25 million

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

fine. In August 2008, the Company paid Hoechst 17 million, including interest of 2 million, in satisfaction of its 20% obligation with respect to the fine.

Based on the advice of external counsel and a review of the existing facts and circumstances relating to the sorbates antitrust matters, including the settlement of the European Union's investigation, as well as civil claims filed and settled, the Company released its accruals related to the settled sorbates antitrust matters and the indemnification receivables resulting in a gain of \$8 million, net, for the year ended December 31, 2008.

In addition, in 2004 a civil antitrust action styled *Freeman Industries LLC v. Eastman Chemical Co., et. al.* was filed against Hoechst and Nutrinova, in the Law Court for Sullivan County in Kingsport, Tennessee. The plaintiff sought monetary damages and other relief for alleged conduct involving the sorbates industry. The trial court dismissed the plaintiff's claims and upon appeal the Supreme Court of Tennessee affirmed the dismissal of the plaintiff's claims. In December 2005, the plaintiff lost an attempt to amend its complaint and the entire action was dismissed with prejudice by the trial court. Plaintiff's counsel has subsequently filed a new complaint with new class representatives in the District Court of the District of Tennessee. The Company's motion to strike the class allegations was granted in April 2008 and the plaintiff's request to appeal the ruling is currently pending.

***Acetic Acid Patent Infringement Matters***

On May 9, 1999, Celanese International Corporation filed a private criminal action styled *Celanese International Corporation v. China Petrochemical Development Corporation* against China Petrochemical Development Corporation (CPDC) in the Taiwan Kaoshiung District Court alleging that CPDC infringed Celanese International Corporation's patent covering the manufacture of acetic acid. Celanese International Corporation also filed a supplementary civil brief which, in view of changes in Taiwanese patent laws, was subsequently converted to a civil action alleging damages against CPDC based on a period of infringement of ten years, 1991-2000, and based on CPDC's own data which was reported to the Taiwanese securities and exchange commission. Celanese International Corporation's patent was held valid by the Taiwanese patent office. On August 31, 2005, the District Court held that CPDC infringed Celanese International Corporation's acetic acid patent and awarded Celanese International Corporation approximately \$28 million (plus interest) for the period of 1995 through 1999. In October 2008, the High Court, on appeal, reversed the District Court's \$28 million award to the Company. The Company appealed to the Superior Court in November 2008, and the court remanded the case to the IP court on June 4, 2009. On January 16, 2006, the District Court awarded Celanese International Corporation \$800,000 (plus interest) for the year 1990. In January 2009, the High Court, on appeal, affirmed the District Court's award and CPDC appealed on February 5, 2009. On June 29, 2007, the District Court awarded Celanese International Corporation \$60 million (plus interest) for the period of 2000 through 2005. CPDC appealed this ruling and on July 21, 2009, the High Court ruled in CPDC's favor.

***Domination Agreement***

On October 1, 2004, a Domination Agreement between Celanese GmbH and Celanese Europe Holding GmbH & Co. KG (the Purchaser) became operative. When the Domination Agreement became operative, the Purchaser became obligated to offer to acquire all outstanding Celanese GmbH shares from the minority shareholders of Celanese GmbH in return for payment of fair cash compensation. The amount of this fair cash compensation was determined to be 41.92 per share, plus interest, in accordance with applicable German law. Until the Squeeze-Out was registered in the

commercial register in Germany on December 22, 2006, any minority shareholder who elected not to sell its shares to the Purchaser was entitled to remain a shareholder of Celanese GmbH and to receive from the Purchaser a gross guaranteed annual payment on its shares of 3.27 per Celanese GmbH share less certain corporate taxes in lieu of any dividend.

The Domination Agreement cannot be terminated by the Purchaser in the ordinary course of business until September 30, 2009. The Company's subsidiaries, Celanese International Holdings Luxembourg S.à r.l. ( CIH ),

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

formerly Celanese Caylux Holdings Luxembourg S.C.A., and Celanese US, have each agreed to provide the Purchaser with financing to strengthen the Purchaser's ability to fulfill its obligations under, or in connection with, the Domination Agreement and to ensure that the Purchaser will perform all of its obligations under, or in connection with, the Domination Agreement when such obligations become due, including, without limitation, the obligation to compensate Celanese GmbH for any statutory annual loss incurred by Celanese GmbH during the term of the Domination Agreement. If CIH and/or Celanese US are obligated to make payments under such guarantees or other security to the Purchaser, the Company may not have sufficient funds for payments on its indebtedness when due. The Company has not had to compensate Celanese GmbH for an annual loss for any period during which the Domination Agreement has been in effect.

The amounts of the fair cash compensation and of the guaranteed annual payment offered under the Domination Agreement are under court review in special award proceedings. As a result of these proceedings, either amount could be increased by the court so that all former Celanese GmbH shareholders, including those who have already tendered their shares into the mandatory offer and have received the fair cash compensation could claim the respective higher amounts. Certain former Celanese GmbH shareholders may initiate such proceedings also with respect to the Squeeze-Out compensation. In this case, former Celanese GmbH shareholders who ceased to be shareholders of Celanese GmbH due to the Squeeze-Out are entitled, pursuant to a settlement agreement between the Purchaser and certain former Celanese GmbH shareholders, to claim for their shares the higher of the compensation amounts determined by the court in these different proceedings. Payments these shareholders already received as compensation for their shares will be offset so that those shareholders who ceased to be shareholders of Celanese GmbH due to the Squeeze-Out are not entitled to more than the higher of the amount set in the two court proceedings.

***Shareholder Litigation***

The amounts of the fair cash compensation and of the guaranteed annual payment offered under the Domination Agreement may be increased in special award proceedings initiated by minority shareholders, which may further reduce the funds the Purchaser can otherwise make available to the Company. As of March 30, 2005, several minority shareholders of Celanese GmbH had initiated special award proceedings seeking the court's review of the amounts of the fair cash compensation and of the guaranteed annual payment offered under the Domination Agreement. As a result of these proceedings, the amount of the fair cash consideration and the guaranteed annual payment offered under the Domination Agreement could be increased by the court so that all minority shareholders, including those who have already tendered their shares into the mandatory offer and have received the fair cash compensation could claim the respective higher amounts. The court dismissed all of these proceedings in March 2005 on the grounds of inadmissibility. Thirty-three plaintiffs appealed the dismissal, and in January 2006, twenty-three of these appeals were granted by the court. They were remanded back to the court of first instance, where the valuation will be further reviewed. On December 12, 2006, the court of first instance appointed an expert to help determine the value of Celanese GmbH. In the first quarter of 2007, certain minority shareholders that received €66.99 per share as fair cash compensation also filed award proceedings challenging the amount they received as fair cash compensation.

The Company received applications for the commencement of award proceedings filed by 79 shareholders against the Purchaser with the Frankfurt District Court requesting the court to set a higher amount for the Squeeze-Out compensation. The motions are based on various alleged shortcomings and mistakes in the valuation of Celanese GmbH done for purposes of the Squeeze-Out. On May 11, 2007, the court of first instance appointed a common



representative for those shareholders that have not filed an application on their own. The Company anticipates a report by the valuation expert before the end of 2009.

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

***Polyester Staple Antitrust Litigation***

CNA Holdings, the successor in interest to Hoechst Celanese Corporation ( HCC ), Celanese Americas Corporation and Celanese GmbH (collectively, the Celanese Entities ) and Hoechst, the former parent of HCC, were named as defendants in two actions (involving 25 individual participants) filed in September 2006 by US purchasers of polyester staple fibers manufactured and sold by HCC. The actions allege that the defendants participated in a conspiracy to fix prices, rig bids and allocate customers of polyester staple sold in the United States. These actions were consolidated in a proceeding by a Multi-District Litigation Panel in the United States District Court for the Western District of North Carolina styled *In re Polyester Staple Antitrust Litigation*, MDL 1516. On June 12, 2008 the court dismissed these actions against all Celanese Entities in consideration of a payment by the Company of \$107 million. This proceeding related to sales by the polyester staple fibers business which Hoechst sold to KoSa, Inc. in 1998. Accordingly, the impact of this settlement is reflected within discontinued operations in the consolidated statements of operations. The Company also previously entered into tolling arrangements with four other alleged US purchasers of polyester staple fibers manufactured and sold by the Celanese Entities. These purchasers were not included in the settlement and one such company filed suit against the Company in December 2008 in the Western District of North Carolina entitled *Milliken & Company v. CNA Holdings, Inc., Celanese Americas Corporation and Hoechst AG* (No. 8-CV-00578). The Company is actively defending this matter.

In 1998, HCC sold its polyester staple business as part of the sale of its Film & Fibers Division to KoSa B.V., f/k/a Arteva B.V. and a subsidiary of Koch Industries, Inc. ( KoSa ). In March 2001 the US Department of Justice ( DOJ ) commenced an investigation of possible price fixing regarding the sales of polyester staple fibers in the US subsequent to the period the Celanese Entities were engaged in the polyester staple fiber business. The Celanese Entities were never named in the DOJ action. As a result of the DOJ action, during August of 2002, Arteva Specialties, S.à.r.l., a subsidiary of KoSa, ( Arteva Specialties ) pled guilty to criminal violation of the Sherman Act related to anti-competitive conduct occurring after the 1998 sale of the polyester staple fiber business and paid a fine of \$29 million. In a complaint pending against the Celanese Entities and Hoechst in the United States District Court for the Southern District of New York, Koch Industries, Inc., KoSa, Arteva Specialties and Arteva Services S.à.r.l. seek damages in excess of \$371 million which includes indemnification for all damages related to the defendants' alleged participation in, and failure to disclose, the alleged conspiracy during due diligence.

***Guarantees***

The Company has agreed to guarantee or indemnify third parties for environmental and other liabilities pursuant to a variety of agreements, including asset and business divestiture agreements, leases, settlement agreements and various agreements with affiliated companies. Although many of these obligations contain monetary and/or time limitations, others do not provide such limitations.

As indemnification obligations often depend on the occurrence of unpredictable future events, the future costs associated with them cannot be determined at this time.

The Company has accrued for all probable and reasonably estimable losses associated with all known matters or claims that have been brought to its attention. These known obligations include the following:

***Demerger Obligations***

The Company has obligations to indemnify Hoechst, and its legal successors, for various liabilities under the Demerger Agreement, including for environmental liabilities associated with contamination arising under 19 divestiture agreements entered into by Hoechst prior to the demerger.

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

The Company's obligation to indemnify Hoechst, and its legal successors, is subject to the following thresholds:

The Company will indemnify Hoechst, and its legal successors, against those liabilities up to 250 million;

Hoechst, and its legal successors, will bear those liabilities exceeding 250 million; however, the Company will reimburse Hoechst, and its legal successors, for one-third of those liabilities for amounts that exceed 750 million in the aggregate.

The aggregate maximum amount of environmental indemnifications under the remaining divestiture agreements that provide for monetary limits is approximately 750 million. Three of the divestiture agreements do not provide for monetary limits.

Based on the estimate of the probability of loss under this indemnification, the Company had reserves of \$33 million and \$27 million as of June 30, 2009 and December 31, 2008, respectively, for this contingency. Where the Company is unable to reasonably determine the probability of loss or estimate such loss under an indemnification, the Company has not recognized any related liabilities.

The Company has also undertaken in the Demerger Agreement to indemnify Hoechst and its legal successors for liabilities that Hoechst is required to discharge, including tax liabilities, which are associated with businesses that were included in the demerger but were not demerged due to legal restrictions on the transfers of such items. These indemnities do not provide for any monetary or time limitations. The Company has not provided for any reserves associated with this indemnification as it is not probable or estimable. The Company has not made any payments to Hoechst or its legal successors during the six months ended June 30, 2009 or 2008 in connection with this indemnification.

***Divestiture Obligations***

The Company and its predecessor companies agreed to indemnify third-party purchasers of former businesses and assets for various pre-closing conditions, as well as for breaches of representations, warranties and covenants. Such liabilities also include environmental liability, product liability, antitrust and other liabilities. These indemnifications and guarantees represent standard contractual terms associated with typical divestiture agreements and, other than environmental liabilities, the Company does not believe that they expose the Company to any significant risk.

The Company has divested numerous businesses, investments and facilities through agreements containing indemnifications or guarantees to the purchasers. Many of the obligations contain monetary and/or time limitations, ranging from one year to thirty years. The aggregate amount of guarantees provided for under these agreements is approximately \$2.3 billion as of June 30, 2009. Other agreements do not provide for any monetary or time limitations.

Based on historical claims experience and its knowledge of the sites and businesses involved, the Company believes that it is adequately reserved for these matters. As of June 30, 2009 and December 31, 2008, the Company has reserves in the aggregate of \$32 million and \$33 million, respectively, for these matters.

***Other Obligations***

The Company is secondarily liable under a lease agreement that the Company assigned to a third party. The lease expires on April 30, 2012. The lease liability for the period from July 1, 2009 to April 30, 2012 is estimated to be approximately \$21 million.

**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

The Company has agreed to indemnify various insurance carriers for amounts not in excess of the settlements received from claims made against these carriers subsequent to the settlement. The aggregate amount of guarantees under these settlements which is limited in term is approximately \$10 million.

***Asbestos Claims***

As of June 30, 2009, Celanese Ltd. and/or CNA Holdings, LLC, both US subsidiaries of the Company, are defendants in approximately 555 asbestos cases. During the six months ended June 30, 2009, 38 new cases were filed against the Company and 42 cases were resolved. Because many of these cases involve numerous plaintiffs, the Company is subject to claims significantly in excess of the number of actual cases. The Company has reserves for defense costs related to claims arising from these matters. The Company believes that there is no significant exposure related to these matters.

***Purchase Obligations***

In the normal course of business, the Company enters into commitments to purchase goods and services over a fixed period of time. The Company maintains a number of take-or-pay contracts for purchases of raw materials and utilities. As of June 30, 2009, there were outstanding future commitments of \$1,746 million under take-or-pay contracts. The Company does not expect to incur any material losses under these contractual arrangements and historically has not incurred any material losses related to these contracts. Additionally, as of June 30, 2009, there were outstanding commitments relating to capital projects of \$19 million.

**13. Derivative Financial Instruments**

To reduce the interest rate risk inherent in the Company's variable rate debt, the Company utilizes interest rate swap agreements to convert a portion of the variable rate debt to a fixed rate obligation. These interest rate swap agreements are designated as cash flow hedges. The notional value of the Company's US dollar interest rate swap agreements at June 30, 2009 and December 31, 2008 was \$1.6 billion and \$1.8 billion, respectively. The notional value of the Company's Euro interest rate swap agreement was 150 million at both June 30, 2009 and December 31, 2008.

If an interest rate swap agreement is terminated prior to its maturity, the amount previously recorded in Accumulated other comprehensive income (loss), net is recognized into earnings over the period that the hedged transaction impacts earnings. If the hedging relationship is discontinued because it is probable that the forecasted transaction will not occur according to the original strategy, any related amounts previously recorded in Accumulated other comprehensive income (loss), net are recognized into earnings immediately.

To protect the foreign currency exposure of a net investment in a foreign operation, the Company entered into cross currency swaps with certain financial institutions in 2004. The cross currency swaps and the Euro-denominated portion of the senior term loan were designated as a hedge of a net investment of a foreign operation. Under the terms of the cross currency swap arrangements, the Company paid approximately 13 million in interest and received approximately \$16 million in interest on June 15 and December 15 of each year. Upon maturity of the cross currency swap agreements in June 2008, the Company owed 276 million (\$426 million) and was owed \$333 million. In settlement of the obligation, the Company paid \$93 million (net of interest of \$3 million) in June 2008.

During the year ended December 31, 2008, the Company dedesignated 385 million of the 400 Euro-denominated portion of the term loan, previously designated as a hedge of a net investment of a foreign operation. The remaining 15 million Euro-denominated portion of the term loan was dedesignated as a hedge of a net investment of a foreign operation in June 2009. Prior to the dedesignations, the Company had been using external derivative contracts to offset foreign currency exposures on certain intercompany loans. As a result of the

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

dedesignations, the foreign currency exposure created by the Euro-denominated term loan is expected to offset the foreign currency exposure on certain intercompany loans, decreasing the need for external derivative contracts and reducing the Company's exposure to external counterparties.

The Company enters into foreign currency forwards and swaps to minimize its exposure to foreign currency fluctuations. Through these instruments, the Company mitigates its foreign currency exposure on transactions with third party entities as well as intercompany transactions. The forward currency forwards and swaps are not designated as hedges under SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities* ( SFAS No. 133 ). Gains and losses on foreign currency forwards and swaps entered into to offset foreign exchange impacts on intercompany balances are classified as Other income (expense), net, in the unaudited interim consolidated statements of operations. Gains and losses on foreign currency forwards and swaps entered into to offset foreign exchange impacts on all other assets and liabilities are classified as Foreign exchange gain (loss), net, in the unaudited interim consolidated statements of operations. The notional value of the Company's foreign currency forwards and swaps at June 30, 2009 and December 31, 2008 were both \$1 billion.

The following table presents information regarding changes in the fair value of the Company's derivative arrangements:

	<b>Three Months Ended June 30, 2009</b>		<b>Six Months Ended June 30, 2009</b>	
	<b>Gain (Loss) Recognized in Other Comprehensive Income</b>	<b>Gain (Loss) Recognized in Income (In \$ millions)</b>	<b>Gain (Loss) Recognized in Other Comprehensive Income</b>	<b>Gain (Loss) Recognized in Income</b>
Derivatives designated as cash flow hedging instruments				
Interest rate swaps	2	(15) <sup>(1)</sup>	(13)	(27) <sup>(1)</sup>
Derivatives designated as net investment hedging instruments				
Euro-denominated term loan	(1)			
Derivatives not designated as hedging instruments				
Foreign currency forwards and swaps		(6)		(15)
<b>Total</b>	<b>1</b>	<b>(21)</b>	<b>(13)</b>	<b>(42)</b>



(1) Amount represents reclassification from Accumulated other comprehensive income and is classified as interest expense in the unaudited interim consolidated statement of operations.

See Note 14, Fair Value Measurements, for additional information regarding the fair value of the Company's derivative arrangements.

#### **14. Fair Value Measurements**

On January 1, 2009, the Company adopted the provisions of SFAS No. 157 for nonrecurring fair value measurements of non-financial assets and liabilities, such as goodwill, indefinite-lived intangible assets, property, plant and equipment and asset retirement obligations. The adoption did not have a material impact on the Company's financial position, results of operations or cash flows.

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

SFAS No. 157 establishes a three-tiered fair value hierarchy that prioritizes inputs to valuation techniques used in fair value calculations. The three levels of inputs are defined as follows:

Level 1 unadjusted quoted prices for identical assets or liabilities in active markets accessible by the Company

Level 2 inputs that are observable in the marketplace other than those inputs classified as Level 1

Level 3 inputs that are unobservable in the marketplace and significant to the valuation

SFAS No. 157 requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.

The Company's financial assets and liabilities are measured at fair value on a recurring basis and include securities available for sale and derivative financial instruments. Securities available for sale include US government and corporate bonds, mortgage-backed securities and equity securities. Derivative financial instruments include interest rate swaps and foreign currency forwards and swaps.

*Marketable Securities.* Where possible, the Company utilizes quoted prices in active markets to measure debt and equity securities; such items are classified as Level 1 in the hierarchy and include equity securities and US government bonds. When quoted market prices for identical assets are unavailable, varying valuation techniques are used. Common inputs in valuing these assets include, among others, benchmark yields, issuer spreads, forward mortgage-backed securities trade prices and recently reported trades. Such assets are classified as Level 2 in the hierarchy and typically include mortgage-backed securities, corporate bonds and other US government securities.

*Derivatives.* Derivative financial instruments are valued in the market using discounted cash flow techniques. These techniques incorporate Level 1 and Level 2 inputs such as interest rates and foreign currency exchange rates. These market inputs are utilized in the discounted cash flow calculation considering the instrument's term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation for interest rate swaps and foreign currency forwards and swaps are observable in the active markets and are classified as Level 2 in the hierarchy.

The following fair value hierarchy tables present information about the Company's assets and liabilities measured at fair value on a recurring basis:

<b>Fair Value Measurement Using Quoted Prices in Active Markets for Identical Assets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Total</b>
--	--	--------------

(In \$ millions)

Marketable securities, at fair value			
Debt securities			
US government		33	33
US corporate		1	1
Equity securities	43		43
Money market deposits and other securities		5	5
Derivatives not designated as hedging instruments			
Foreign currency forwards and swaps (included in current			
Other assets)		8	8
Total assets as of June 30, 2009	43	47	90

Table of Contents**CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

	<b>Fair Value Measurement Using Quoted Prices in Active Markets for Identical Assets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2) (In \$ millions)</b>	<b>Total</b>
Derivatives designated as cash flow hedging instruments			
Interest rate swaps (included in current Other liabilities)		(62)	(62)
Interest rate swaps (included in noncurrent Other liabilities)		(54)	(54)
Derivatives not designated as hedging instruments			
Foreign currency forwards and swaps (included in current Other liabilities)		(17)	(17)
Total liabilities as of June 30, 2009		(133)	(133)
Marketable securities, at fair value			
Debt securities			
US government		52	52
US corporate		3	3
Equity securities	42		42
Money market deposits and other securities		3	3
Derivatives not designated as hedging instruments			
Foreign currency forwards and swaps (included in current Other assets)		54	54
Total assets as of December 31, 2008	42	112	154
Derivatives designated as cash flow hedging instruments			
Interest rate swaps (included in current Other liabilities)		(42)	(42)
Interest rate swaps (included in noncurrent Other liabilities)		(76)	(76)
Derivatives not designated as hedging instruments			
Foreign currency forwards and swaps (included in current Other liabilities)		(25)	(25)
Total liabilities as of December 31, 2008		(143)	(143)

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

Summarized below are the carrying values and estimated fair values of financial instruments that are not carried at fair value on our consolidated balance sheets:

	<b>As of June 30, 2009</b>		<b>As of December 31, 2008</b>	
	<b>Carrying Amount</b>	<b>Fair Value (In \$ millions)</b>	<b>Carrying Amount</b>	<b>Fair Value</b>
Cost investments	185		184	
Insurance contracts in nonqualified pension trusts	64	64	67	67
Long-term debt, including current installments of long-term debt	3,340	3,072	3,381	2,404

In general, the cost investments included in the table above are not publicly traded and their fair values are not readily determinable; however, the Company believes the carrying values approximate or are less than the fair values.

As of June 30, 2009 and December 31, 2008, the fair values of cash and cash equivalents, receivables, trade payables, short-term debt and the short-term borrowings approximate carrying values due to the short-term nature of these instruments. These items have been excluded from the table. Additionally, certain noncurrent receivables, principally insurance recoverables, are carried at net realizable value.

The fair value of long-term debt is based on valuations from third-party banks and market quotations.

**15. Other (Charges) Gains, Net**

The components of Other (charges) gains, net are as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
	<b>(In \$ millions)</b>			
Employee termination benefits	(5)	(4)	(29)	(11)
Plant/office closures				(7)
Ticona Kelsterbach plant relocation (see Note 19)	(3)	(3)	(6)	(5)
Plumbing actions	2		3	
Insurance recoveries associated with Clear Lake, Texas			6	
Asset impairments			(1)	
Total	(6)	(7)	(27)	(23)

During the first quarter of 2009, the Company began efforts to align production capacity and staffing levels with the Company's view of an economic environment of prolonged lower demand. For the six months ended June 30, 2009, Other charges included employee termination benefits of \$28 million related to this endeavor. As a result of the shutdown of the vinyl acetate monomer ( VAM ) production unit in Cangrejera, Mexico, the Company recognized employee termination benefits of \$1 million and long-lived asset impairment losses of \$1 million during the six months ended June 30, 2009. The VAM production unit in Cangrejera, Mexico is included in the Company's Acetyl Intermediates segment.

Other charges for the six months ended June 30, 2009 was partially offset by \$6 million of insurance recoveries in satisfaction of claims the Company made related to the unplanned outage of the Company's Clear Lake, Texas

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

acetic acid facility during 2007, a \$2 million decrease in legal reserves for plumbing claims for which the statute of limitations has expired and \$1 million of insurance recoveries associated with plumbing cases.

Employee termination benefits during 2008 related primarily to the Company's strategy to simplify and optimize its business portfolio. Plant/office closures during 2008 included accelerated depreciation expense related to the shutdown of the Company's Pampa, Texas facility.

The changes in the restructuring reserves by business segment are as follows:

	<b>Advanced Engineered Materials</b>	<b>Consumer Specialties</b>	<b>Industrial Specialties</b>	<b>Acetyl Intermediates</b>	<b>Other</b>	<b>Total</b>
	<b>(In \$ millions)</b>					
<b>Employee Termination Benefits</b>						
Employee termination benefits reserve as of December 31, 2008	2	2	6	17	2	29
Restructuring additions	10	3	3	6	7	29
Cash payments	(4)	(2)	(6)	(19)	(3)	(34)
Employee termination benefits reserve as of June 30, 2009	8	3	3	4	6	24
<b>Plant/Office Closures</b>						
Plant/Office closures reserve as of December 31, 2008		2			1	3
Transfer to demolition accrual (current Other liabilities)		(2)				(2)
Cash payments						
Plant/Office closures reserve as of June 30, 2009					1	1
Total Restructuring reserves as of June 30, 2009	8	3	3	4	7	25

**16. Income Taxes**

The Company's effective income tax rate for the three months ended June 30, 2009 was 14% compared to 18% for the three months ended June 30, 2008. The Company's effective income tax rate for the six months ended June 30, 2009 was 21% compared to 25% for the six months ended June 30, 2008. The decrease in the effective rate is primarily due

to a decrease in additions to liabilities for unrecognized tax benefits and related interest, partially offset by an increase in valuation allowances on certain foreign net deferred tax assets and lower earnings in jurisdictions participating in tax holidays.

Liabilities for unrecognized tax benefits and related interest and penalties are recorded in Uncertain tax positions and current Other liabilities in the consolidated balance sheets. For the six months ended June 30, 2009, the total unrecognized tax benefits, interest and penalties increased by \$16 million of which \$4 million related to currency translation adjustments. The Company expects to resolve certain tax matters within the next twelve months due to the conclusion of tax examinations. As of June 30, 2009 there was a \$5 million reserve for uncertain tax positions included in current Other liabilities.

Equity in net earnings (loss) of affiliates included \$19 million in earnings related to a one-time reversal of deferred tax liabilities associated with the Company's Polyplastics Co., Ltd equity-method investee due to a foreign



**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

tax law enactment. The Company's Polyplastics Co., Ltd equity-method investment is included in the Advanced Engineered Materials segment.

**17. Business Segments**

	<b>Advanced Engineered Materials</b>	<b>Consumer Specialties</b>	<b>Industrial Specialties</b>	<b>Acetyl Intermediates</b>	<b>Other Activities</b>	<b>Eliminations</b>	<b>Consolidated</b>
	<b>(In \$ millions)</b>						
Three months ended June 30, 2009							
Net sales	184	280	267	622 <sup>(1)</sup>	1	(110)	1,244
Other (charges) gains, net	(4)	(3)	(1)		2		(6)
Equity in net earnings (loss) of affiliates	23			1	3		27
Earnings (loss) from continuing operations before tax	23	119	19	44	(83)		122
Depreciation and amortization	19	12	14	32	2		79
Capital expenditures <sup>(3)</sup>	6	10	16	9	1		42
Three months ended June 30, 2008							
Net sales	300	292	386	1,067 <sup>(1)</sup>	1	(178)	1,868
Other (charges) gains, net	(3)		(1)	(2)	(1)		(7)
Equity in net earnings (loss) of affiliates	11	1		1	4		17
Earnings (loss) from continuing operations before tax	48	94	20	181	(96)		247
Depreciation and amortization	19	13	14	34	2		82
Capital expenditures <sup>(4)</sup>	14	10	18	17	1		60

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

	<b>Advanced</b>						
	<b>Engineered</b>	<b>Consumer</b>	<b>Industrial</b>	<b>Acetyl</b>	<b>Other</b>	<b>Elimination</b>	<b>Consolidated</b>
	<b>Materials</b>	<b>Specialties</b>	<b>Specialties</b>	<b>Intermediates</b>	<b>Activities</b>		
	<b>(In \$ millions)</b>						
Six months ended							
June 30, 2009							
Net sales	349	546	509	1,194 <sup>(2)</sup>	1	(209)	2,390
Other (charges) gains, net	(13)	(3)	(3)	(1)	(7)		(27)
Equity in net earnings (loss)							
of affiliates	15	1		3	6		25
Earnings (loss) from							
continuing operations before							
tax	(4)	188	29	60	(167)		106
Depreciation and							
amortization	36	24	27	59	4		150
Capital expenditures <sup>(3)</sup>	10	18	26	17	1		72
Goodwill and intangible							
assets	391	305	66	354			1,116
Total assets	1,965	1,115	924	1,945	1,674		7,623
Six months ended							
June 30, 2008							
Net sales	594	574	751	2,163 <sup>(2)</sup>	1	(369)	3,714
Other (charges) gains, net	(6)	(1)	(4)	(9)	(3)		(23)
Equity in net earnings (loss)							
of affiliates	20	1		1	5		27
Earnings (loss) from							
continuing operations before							
tax	87	144	37	387	(190)		465
Depreciation and							
amortization	39	27	28	66	5		165
Capital expenditures <sup>(4)</sup>	27	20	29	41	4		121
Goodwill and intangible							
assets as of December 31,							
2008	398	309	73	363			1,143
Total assets as of							
December 31, 2008	1,867	995	903	2,197	1,204		7,166

<sup>(1)</sup> Includes \$110 million and \$178 million of inter-segment sales eliminated in consolidation for the three months ended June 30, 2009 and 2008, respectively.

- (2) Includes \$209 million and \$369 million of inter-segment sales eliminated in consolidation for the six months ended June 30, 2009 and 2008, respectively.
- (3) Includes increase of \$2 million and decrease of \$24 million in accrued capital expenditures for the three and six months ended June 30, 2009, respectively.
- (4) Includes increase of \$5 million and decrease of \$15 million in accrued capital expenditures for the three and six months ended June 30, 2008, respectively.

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)****18. Earnings Per Share**

	<b>Three Months Ended June 30,</b>			
	<b>2009</b>		<b>2008</b>	
	<b>Basic</b>	<b>Diluted</b>	<b>Basic</b>	<b>Diluted</b>
	<b>(In \$ millions, except for share and per share data)</b>			
Amounts attributable to Celanese Corporation				
Earnings (loss) from continuing operations	105	105	203	203
Earnings (loss) from discontinued operations	(1)	(1)	(69)	(69)
Net earnings (loss)	104	104	134	134
Less: cumulative preferred stock dividends	(2)		(2)	
Net earnings (loss) available to common shareholders	102	104	132	134
Weighted-average shares basic	143,528,126	143,528,126	150,905,770	150,905,770
Dilutive stock options		1,020,493		4,089,106
Dilutive restricted stock units		445,014		768,053
Assumed conversion of preferred stock		12,084,337		12,051,874
Weighted-average shares diluted		157,077,970		167,814,803
Per share				
Earnings (loss) from continuing operations	0.72	0.67	1.33	1.21
Earnings (loss) from discontinued operations	(0.01)	(0.01)	(0.46)	(0.41)
Net earnings (loss)	0.71	0.66	0.87	0.80

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

	<b>Six Months Ended June 30,</b>			
	<b>2009</b>		<b>2008</b>	
	<b>Basic</b>	<b>Diluted</b>	<b>Basic</b>	<b>Diluted</b>
	<b>(In \$ millions, except for share and per share data)</b>			
Amounts attributable to Celanese Corporation				
Earnings (loss) from continuing operations	84	84	348	348
Earnings (loss) from discontinued operations			(69)	(69)
Net earnings (loss)	84	84	279	279
Less: cumulative preferred stock dividends	(5)		(5)	
Net earnings (loss) available to common shareholders	79	84	274	279
Weighted-average shares basic	143,517,588	143,517,588	151,449,762	151,449,762
Dilutive stock options		510,246		3,434,591
Dilutive restricted stock units		242,878		625,566
Assumed conversion of preferred stock		12,084,337		12,051,874
Weighted-average shares diluted		156,355,049		167,561,793
Per share				
Earnings (loss) from continuing operations	0.55	0.54	2.26	2.08
Earnings (loss) from discontinued operations			(0.45)	(0.41)
Net earnings	0.55	0.54	1.81	1.67

The following securities were not included in the computation of diluted net earnings per share as their effect would have been antidilutive:

<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>

Edgar Filing: Celanese CORP - Form 10-Q

Stock options	1,583,113	109,973	4,262,531	119,556
Restricted stock units	88,250		358,127	
Convertible preferred stock				
Total	1,671,363	109,973	4,620,658	119,556

32

---

**Table of Contents****CELANESE CORPORATION AND SUBSIDIARIES****NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)****19. Ticona Kelsterbach Plant Relocation**

In 2007, the Company finalized a settlement agreement with the Frankfurt, Germany, Airport ( Fraport ) to relocate the Kelsterbach, Germany Ticona business, included in the Advanced Engineered Materials segment, resolving several years of legal disputes related to the planned Fraport expansion. As a result of the settlement, the Company will transition Ticona s operations from Kelsterbach to the Hoechst Industrial Park in the Rhine Main area in Germany by mid-2011. Under the original agreement, Fraport agreed to pay Ticona a total of 670 million over a five-year period to offset the costs associated with the transition of the business from its current location and the closure of the Kelsterbach plant. In February 2009, the Company announced the Fraport supervisory board approved the acceleration of the 2009 and 2010 payments of 200 million and 140 million, respectively, required by the settlement agreement signed in June 2007. In February 2009, the Company received a discounted amount of 322 million (\$412 million) under this agreement. Amounts received from Fraport are accounted for as deferred proceeds and are included in noncurrent Other liabilities in the unaudited consolidated balance sheets. In addition, the Company received 59 million (\$75 million) in value-added tax from Fraport which was remitted to the tax authorities in April 2009.

Below is a summary of the financial statement impact associated with the Ticona Kelsterbach plant relocation:

	<b>Six Months Ended</b>		<b>Total From</b>
	<b>June 30,</b>		<b>Inception</b>
	<b>2009</b>	<b>2008</b>	<b>Through</b>
	<b>(In \$ millions)</b>		<b>June 30, 2009</b>
Proceeds received from Fraport	412	311	749
Costs expensed	6	5	23
Costs capitalized <sup>(1)</sup>	162	62	405

<sup>(1)</sup> Includes an increase in accrued capital expenditures of \$15 million for the six months ended June 30, 2009 and no change in accrued capital expenditures for the six months ended June 30, 2008.

**20. Subsequent Events**

On July 2, 2009, the Company declared a cash dividend of \$0.265625 per share on its 4.25% convertible perpetual preferred stock amounting to \$3 million and a cash dividend of \$0.04 per share on its Series A common stock amounting to \$6 million. Both cash dividends are for the period from May 1, 2009 to July 31, 2009 and will be paid on August 3, 2009 to holders of record as of July 15, 2009.

On July 1, 2009, the Company announced the completion of the sale of its polyvinyl alcohol ( PVOH ) business to Sekisui Chemical Co., Ltd. for a cash purchase price of approximately \$173 million, excluding the value of accounts receivable and payable retained by the Company. The transaction includes long-term supply agreements between both

companies. This transaction is not expected to be material to the financial position of the Company, but may be material to the results of operations for any given period. The PVOH business is included in the Industrial Specialties segment. Included in Assets held for sale at June 30, 2009 is \$96 million of property, plant, and equipment and \$37 million of inventories related to the sale of the PVOH business.

On July 8, 2009, the Company announced that its wholly-owned French subsidiary, Acetex Chimie, had completed the consultation procedure with the workers council on its Project of Closure and social plan related to the Company's Pardies, France facility pursuant to which the Company announced its formal intent to cease all manufacturing operations there and its associated activities. The Company has agreed with the workers council on a set of measures of assistance aimed at minimizing the effects of the plant's closing on the Pardies workforce, including training, outplacement, and severance.



**Table of Contents**

**CELANESE CORPORATION AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS (Continued)**

As a result of the Project of Closure, the Company expects to record exit costs of \$90 million to \$100 million, primarily in the second half of 2009, consisting of \$70 million in personnel-related exit costs and \$20 million to \$30 million of other facility-related shutdown costs, which include demolition, remediation, contract termination costs and accelerated depreciation of fixed assets. The Pardies facility is included in the Acetyl Intermediates segment.

Subsequent events have been evaluated through the date of issuance, July 29, 2009.

**Table of Contents**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*In this Quarterly Report on Form 10-Q, the term Celanese refers to Celanese Corporation, a Delaware corporation, and not its subsidiaries. The terms the Company, we, our and us, refer to Celanese and its subsidiaries on a consolidated basis. The term Celanese US refers to our subsidiary, Celanese US Holdings LLC, a Delaware limited liability company, formerly known as BCP Crystal US Holdings Corp., a Delaware corporation, and not its subsidiaries. The term Purchaser refers to our subsidiary, Celanese Europe Holding GmbH & Co. KG, formerly known as BCP Crystal Acquisition GmbH & Co. KG, a German limited partnership, and not its subsidiaries, except where otherwise indicated.*

**Forward-Looking Statements May Prove Inaccurate**

Management's Discussion and Analysis of Financial Condition and Results of Operations ( MD&A ) and other parts of this Quarterly Report on Form 10-Q contain certain forward-looking statements and information relating to us that are based on the beliefs of our management as well as assumptions made by, and information currently available to, us. When used in this document, words such as anticipate, believe, estimate, expect, intend, plan and project and expressions, as they relate to us are intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Further, certain forward-looking statements are based upon assumptions as to future events that may not prove to be accurate.

The following discussion should be read in conjunction with the Celanese Corporation and Subsidiaries consolidated financial statements as of and for the year ended December 31, 2008, as filed on February 13, 2009 with the Securities and Exchange Commission ( SEC ) as part of the Company's Annual Report on Form 10-K (the 2008 Form 10-K ) and the unaudited interim consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

See the Risk Factors section under Part II, Item 1A of this Quarterly Report on Form 10-Q for a description of risk factors that could significantly affect our financial results. In addition, the following factors could cause our actual results to differ materially from those results, performance or achievements that may be expressed or implied by such forward-looking statements. These factors include, among other things:

changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate;

the length and depth of product and industry business cycles particularly in the automotive, electrical, electronics and construction industries;

changes in the price and availability of raw materials, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, wood pulp, fuel oil and electricity;

the ability to pass increases in raw material prices on to customers or otherwise improve margins through price increases;

the ability to maintain plant utilization rates and to implement planned capacity additions and expansions;

the ability to reduce production costs and improve productivity by implementing technological improvements to existing plants;

increased price competition and the introduction of competing products by other companies;

changes in the degree of intellectual property and other legal protection afforded to our products;

compliance costs and potential disruption or interruption of production due to accidents or other unforeseen events or delays in construction of facilities;

potential liability for remedial actions under existing or future environmental regulations;

**Table of Contents**

potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate;

changes in currency exchange rates and interest rates; and

various other factors, both referenced and not referenced in this Quarterly Report on Form 10-Q.

Many of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from those described in this Quarterly Report as anticipated, believed, estimated, expected, intended, planned or projected. We neither intend nor assume any obligation to update these forward-looking statements, which speak only as of their dates.

***Overview***

We are a leading global integrated producer of chemicals and advanced materials. We are one of the world's largest producers of acetyl products, which are intermediate chemicals for nearly all major industries, as well as a leading global producer of high-performance engineered polymers that are used in a variety of high-value end-use applications. As an industry leader, we hold geographically balanced global positions and participate in diversified end-use markets. Our operations are primarily located in North America, Europe and Asia. We combine a demonstrated track record of execution, strong performance built on shared principles and objectives, and a clear focus on growth and value creation.

**2009 Significant Events:**

We announced the Frankfurt, Germany, Airport (Fraport) supervisory board approved the acceleration of the 2009 and 2010 payments of 200 million and 140 million, respectively, required by the settlement agreement signed in June 2007. On February 5, 2009, we received a discounted amount of approximately 322 million (\$412 million), excluding value-added tax of 59 million (\$75 million).

We shut down our vinyl acetate monomer (VAM) production unit in Cangrejera, Mexico, and ceased VAM production at the site during the first quarter of 2009.

Standard and Poor's affirmed our ratings and revised our outlook from positive to stable in February 2009.

We received the American Chemistry Council's (ACC) Responsible Care Sustained Excellence Award for mid-size companies. The annual award, the most prestigious award given under ACC's Responsible Care initiative, recognized companies for outstanding leadership under ACC's Environmental Health and Safety performance criteria.

We completed the sale of our polyvinyl alcohol (PVOH) business to Sekisui Chemical Co., Ltd. for the purchase price of approximately \$173 million, excluding the value of accounts receivable and payable retained by Celanese.

We agreed to a Project of Closure for our acetic acid and vinyl acetate monomer production operations at our Pardies, France, site. These operations are expected to cease by December 2009. As a result of the Pardies Project of Closure, we expect to record exit costs of approximately \$90 to \$100 million primarily in the second half of 2009.

We announced that Celanese US has amended its \$650 million revolving credit facility. The amendment lowered the total revolver commitment to \$600 million and increased the first lien senior secured leverage ratio for a period of six quarters, beginning June 30, 2009, and ending December 31, 2010.

We announced the creation of our new and proprietary AOPlus<sup>®2</sup> acetic acid technology, which allows for expansion up to 1.5 million tons per reactor. We also announced plans to double the current capacity of our Nanjing, China acetic acid facility from 600,000 tons to 1.2 million tons by the end of 2009.



Add: Long-term debt	3,268	3,300
Total debt	3,492	3,533

**Summary of Consolidated Results for the Three and Six Months Ended June 30, 2009 compared to the Three and Six Months Ended June 30, 2008**

The economic slowdown that severely impacted the global economy late in 2008 continued to impact net sales and profitability through the second quarter of 2009. Net sales decreased 33% and 36% during the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008, primarily due to lower volumes and unfavorable foreign currency impacts across all segments and lower prices for acetyl intermediates products. Decreased demand for automotive and industrial products drove the decline in volumes. Volume declines occurred primarily in Europe and the Americas. Demand increased in Asia for most of our major acetyl intermediates products. Selling prices during the period were negatively impacted by lower industry utilization of acetyl intermediates products, particularly in Europe and the Americas, coupled with lower raw material prices. Selling price increases for acetate tow, ultra-high molecular weight polyethylene ( GUR® ) and Vectra® liquid crystal polymer ( LCP ) partially offset the overall decline in net sales.

Gross profit declined due to lower net sales, partially offset by decreased raw material and energy costs, and depreciation and amortization across all businesses. Depreciation and amortization declines result partially from the shutdown of our Pampa, Texas facility and the effects of long-lived asset impairment losses recognized during the fourth quarter of 2008 on depreciation.

**Table of Contents**

Selling, general and administrative expenses decreased \$24 million and \$46 million for the three and six months ended June 30, 2009, respectively, compared to the same period in 2008. Selling, general and administrative expenses declined due to our fixed spending reduction efforts, restructuring efficiencies, decreased costs resulting from the shutdown of our Pampa, Texas facility and favorable currency impacts on overall spending.

The components of Other (charges) gains, net are as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
	<b>(In \$ millions)</b>			
Employee termination benefits	(5)	(4)	(29)	(11)
Plant/office closures				(7)
Ticona Kelsterbach plant relocation	(3)	(3)	(6)	(5)
Plumbing actions	2		3	
Insurance recoveries associated with Clear Lake, Texas			6	
Asset impairments			(1)	
<b>Total</b>	<b>(6)</b>	<b>(7)</b>	<b>(27)</b>	<b>(23)</b>

During the first quarter of 2009, we began efforts to align production capacity and staffing levels with our view of an economic environment of prolonged lower demand. For the six months ended June 30, 2009, Other charges included employee termination benefits of \$28 million related to this endeavor. As a result of the shutdown of the VAM production unit in Cangrejera, Mexico, we recognized employee termination benefits of \$1 million and long-lived asset impairment losses of \$1 million during the six months ended June 30, 2009.

Other charges for the six months ended June 30, 2009 was partially offset by \$6 million of insurance recoveries in satisfaction of claims the Company made related to the unplanned outage of the Company's Clear Lake, Texas acetic acid facility during 2007, a \$2 million decrease in legal reserves for plumbing claims for which the statute of limitations has expired and \$1 million of insurance recoveries associated with plumbing cases.

Employee termination benefits during the three months ended June 30, 2009 relates primarily to our strategy to simplify and optimize our business portfolio. Plant/office closures during 2008 included accelerated depreciation expense related to the shutdown of our Pampa, Texas facility.

Operating profit decreased \$118 million and \$325 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008. The decline in operating profit is primarily attributable to a decrease in gross profit due to the global economic downturn. The decline was partially offset by decreased selling, general and administrative expenses.

Earnings (loss) from continuing operations before tax decreased \$125 million and \$359 million during the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008. The decline is primarily due to lower operating profit and reduced dividend income from cost investments offset by \$19 million in earnings related to a one-time reversal of deferred tax liabilities associated with our Polyplastics Co., Ltd equity-method investee due to a foreign tax law enactment. Dividend income from our Acetyl Intermediates segment's cost investment, Ibn Sina,



declined \$27 million and \$50 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008 as a result of lower earnings from declining margins for methanol and methyl tertiary-butyl ether ( MTBE ). A \$9 million and \$25 million reduction in interest expense for the three and six months ended June 30, 2009, respectively, partially offset the decline in Earnings (loss) from continuing operations before tax. The reduction in interest expense is attributable to lower interest rates.

Our effective income tax rate for the three months ended June 30, 2009 was 14% compared to 18% for the three months ended June 30, 2008. Our effective income tax rate for the six months ended June 30, 2009 was 21% compared to 25% for the six months ended June 30, 2008. The decrease in the effective rate is primarily due to a decrease in additions to liabilities for unrecognized tax benefits and related interest, partially offset by an increase in valuation allowances on certain foreign net deferred tax assets and lower earnings in jurisdictions participating in tax holidays.

**Table of Contents****Selected Data by Business Segment**

	Three Months Ended June 30,			Six Months Ended June 30,		
	2009	2008	Change in \$ (unaudited) (In \$ millions)	2009	2008	Change in \$
Net sales						
Advanced Engineered Materials	184	300	(116)	349	594	(245)
Consumer Specialties	280	292	(12)	546	574	(28)
Industrial Specialties	267	386	(119)	509	751	(242)
Acetyl Intermediates	622	1,067	(445)	1,194	2,163	(969)
Other Activities	1	1		1	1	
Inter-segment Eliminations	(110)	(178)	68	(209)	(369)	160
Total	1,244	1,868	(624)	2,390	3,714	(1,324)
Other (charges) gains, net						
Advanced Engineered Materials	(4)	(3)	(1)	(13)	(6)	(7)
Consumer Specialties	(3)		(3)	(3)	(1)	(2)
Industrial Specialties	(1)	(1)		(3)	(4)	1
Acetyl Intermediates		(2)	2	(1)	(9)	8
Other Activities	2	(1)	3	(7)	(3)	(4)
Total	(6)	(7)	1	(27)	(23)	(4)
Operating profit (loss)						
Advanced Engineered Materials		37	(37)	(19)	67	(86)
Consumer Specialties	66	46	20	132	96	36
Industrial Specialties	19	20	(1)	29	37	(8)
Acetyl Intermediates	40	148	(108)	52	325	(273)
Other Activities	(36)	(44)	8	(78)	(84)	6
Total	89	207	(118)	116	441	(325)
Earnings (loss) from continuing operations before tax						
Advanced Engineered Materials	23	48	(25)	(4)	87	(91)
Consumer Specialties	119	94	25	188	144	44
Industrial Specialties	19	20	(1)	29	37	(8)
Acetyl Intermediates	44	181	(137)	60	387	(327)
Other Activities	(83)	(96)	13	(167)	(190)	23
Total	122	247	(125)	106	465	(359)
Depreciation and amortization						

Edgar Filing: Celanese CORP - Form 10-Q

Advanced Engineered Materials	19	19		36	39	(3)
Consumer Specialties	12	13	(1)	24	27	(3)
Industrial Specialties	14	14		27	28	(1)
Acetyl Intermediates	32	34	(2)	59	66	(7)
Other Activities	2	2		4	5	(1)
Total	79	82	(3)	150	165	(15)

**Table of Contents****Factors Affecting Segment Net Sales**

The charts below set forth the percentage increase (decrease) in net sales from the period ended June 30, 2008 to the period ended June 30, 2009 attributable to each of the factors indicated for the following business segments.

	<b>Volume</b>	<b>Price</b>	<b>Currency (unaudited) (In percentages)</b>	<b>Other</b>	<b>Total</b>
Second Quarter 2009 Compared to Second Quarter 2008					
Advanced Engineered Materials	(34)		(5)		(39)
Consumer Specialties	(10)	9	(3)		(4)
Industrial Specialties	(14)	(12)	(5)		(31)
Acetyl Intermediates	(11)	(28)	(3)		(42)
Total Company <sup>(1)</sup>	(16)	(17)	(4)	4	(33)
Six Months Ended June 30, 2009 Compared to Six Months Ended June 30, 2008					
Advanced Engineered Materials	(38)	2	(5)		(41)
Consumer Specialties	(10)	8	(3)		(5)
Industrial Specialties	(20)	(7)	(5)		(32)
Acetyl Intermediates	(15)	(27)	(3)		(45)
Total Company <sup>(1)</sup>	(20)	(16)	(4)	4	(36)

<sup>(1)</sup> Includes the effects of the captive insurance companies and the impact of fluctuations in intersegment eliminations.

**Summary by Business Segment for the Three and Six Months Ended June 30, 2009 compared to the Three and Six Months Ended June 30, 2008*****Advanced Engineered Materials***

	<b>Three Months Ended June 30,</b>			<b>Six Months Ended June 30,</b>		
	<b>2009</b>	<b>2008</b>	<b>Change in \$ (unaudited)</b>	<b>2009</b>	<b>2008</b>	<b>Change in \$</b>
	<b>(In \$ millions, except for percentages)</b>					
Net sales	184	300	(116)	349	594	(245)
Net sales variance						
<i>Volume</i>	(34)%			(38)%		
<i>Price</i>				2%		
<i>Currency</i>	(5)%			(5)%		
<i>Other</i>						

Edgar Filing: Celanese CORP - Form 10-Q

Other (charges) gains, net	(4)	(3)	(1)	(13)	(6)	(7)
Operating profit		37	(37)	(19)	67	(86)
Operating margin		12.3%		(5.4)%	11.3%	
Earnings (loss) from continuing operations before tax	23	48	(25)	(4)	87	(91)
Depreciation and amortization	19	19		36	39	(3)

Our Advanced Engineered Materials segment develops, produces and supplies a broad portfolio of high performance technical polymers for application in automotive and electronics products, as well as other consumer and industrial applications. Together with our strategic affiliates, we are a leading participant in the global technical polymers industry. The primary products of Advanced Engineered Materials are polyacetal products ( POM ),

**Table of Contents**

polyphenylene sulfide ( PPS ), long fiber reinforced thermoplastics ( LFRT ), polybutylene terephthalate ( PBT ), polyethylene terephthalate ( PET ), GUR<sup>®</sup> and LCP. POM, PPS, LFRT, PBT and PET are used in a broad range of products including automotive components, electronics, appliances and industrial applications. GUR<sup>®</sup> is used in battery separators, conveyor belts, filtration equipment, coatings and medical devices. Primary end markets for LCP are electrical and electronics.

Advanced Engineered Materials net sales decreased 39% and 41% for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008. Significant weakness in the global economy resulted in a dramatic decline in demand for automotive, electrical and electronic products as well as for other industrial products. As a result, sales volumes dropped significantly across all product lines. The decline in sales volumes for the three months ended June 30, 2009 was less significant than the decline in sales volumes for the three months ended March 31, 2009, indicating that the impact of inventory destocking may be diminishing. Unfavorable foreign currency impacts furthered the decline in net sales.

Operating profit decreased by \$37 million and \$86 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008. Lower raw material and energy costs and decreased overall spending only partially offset the decline in net sales. Decreased overall spending was the result of our fixed spending reduction efforts. Non-capital spending incurred on the relocation of our Ticona plant in Kelsterbach was flat compared to 2008. For more information regarding the Ticona Kelsterbach plant relocation, see Note 19 to the consolidated financial statements.

Our equity affiliates have experienced similar volume reductions due to decreased demand during 2009. As a result, our proportional share of net earnings of these affiliates during the six months ended June 30, 2009 declined \$5 million compared to the same period in 2008. Our equity in net earnings of affiliates included \$19 million in earnings related to a one-time reversal of deferred tax liabilities associated with our Polyplastics Co., Ltd equity-method investee due to a foreign tax law enactment.

**Consumer Specialties**

	Three Months Ended			Six Months Ended		
	2009	2008	Change in \$ (unaudited)	2009	2008	Change in \$
	(In \$ millions, except for percentages)					
Net sales	280	292	(12)	546	574	(28)
Net sales variance						
Volume	(10)%			(10)%		
Price	9%			8%		
Currency	(3)%			(3)%		
Other						
Other (charges) gains, net	(3)		(3)	(3)	(1)	(2)
Operating profit	66	46	20	132	96	36
Operating margin	23.6%	15.8%		24.2%	16.7%	
Earnings (loss) from continuing operations before tax	119	94	25	188	144	44
Depreciation and amortization	12	13	(1)	24	27	(3)

Our Consumer Specialties segment consists of our Acetate Products and Nutrinova businesses. Our Acetate Products business primarily produces and supplies acetate tow, which is used in the production of filter products. We also produce acetate flake which is processed into acetate fiber in the form of a tow band. Our Nutrinova business produces and sells Sunett<sup>®</sup>, a high intensity sweetener, and food protection ingredients, such as sorbates, for the food, beverage and pharmaceuticals industries.

Decreased volumes in our Acetate and Nutrinova businesses and unfavorable foreign currency impacts contributed to decreased net sales during the three and six month periods ended June 30, 2009 as compared to 2008.

**Table of Contents**

Decreased volumes were primarily due to weakness in underlying demand resulting from the global economic downturn. Decreased flake and tow volumes were substantially offset by increased tow pricing during the period.

Operating profit increased by \$20 million and \$36 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008 largely due to increased tow pricing. Decreased plant spending and improved energy costs also contributed to the increase.

During the three and six month period ended June 30, 2009, earnings from continuing operations before tax increased due to increased operating profit as well as higher dividends from our China ventures of \$7 million and \$10 million, respectively.

**Industrial Specialties**

	Three Months Ended June 30,			Six Months Ended June 30,		
	2009	2008	Change in \$ (unaudited)	2009	2008	Change in \$
	(In \$ millions, except for percentages)					
Net sales	267	386	(119)	509	751	(242)
Net sales variance						
<i>Volume</i>	(14)%			(20)%		
<i>Price</i>	(12)%			(7)%		
<i>Currency</i>	(5)%			(5)%		
<i>Other</i>						
Other (charges) gains, net	(1)	(1)		(3)	(4)	1
Operating profit	19	20	(1)	29	37	(8)
Operating margin	7.1%	5.2%		5.7%	4.9%	
Earnings (loss) from continuing operations before tax	19	20	(1)	29	37	(8)
Depreciation and amortization	14	14		27	28	(1)

Our Industrial Specialties segment includes our Emulsions, PVOH and AT Plastics businesses. Our Emulsions business is a global leader which produces a broad product portfolio, specializing in vinyl acetate ethylene emulsions, and is a recognized authority on low volatile organic compounds ( VOC ), an environmentally-friendly technology. As a global leader, our PVOH business produces a broad portfolio of performance PVOH chemicals engineered to meet specific customer requirements. Our emulsions and PVOH products are used in a wide array of applications including paints and coatings, adhesives, construction, glass fiber, textiles and paper. AT Plastics offers a complete line of low-density polyethylene and specialty ethylene vinyl acetate resins and compounds. AT Plastics products are used in many applications including flexible packaging films, lamination film products, hot melt adhesives, medical tubing, automotive carpeting and solar cell encapsulation films.

On July 1, 2009, we announced the completion of the sale of our PVOH business to Sekisui Chemical Co., Ltd. for a cash purchase price of approximately \$173 million, excluding the value of accounts receivable and payable retained by Celanese. The transaction includes long-term supply agreements between both companies. This transaction is not expected to be material to our financial position, but may be material to our 2009 results of operations. At June 30, 2009, we classified \$96 million of property, plant, and equipment and \$37 million of inventories related to the sale of



PVOH as Assets held for sale in the unaudited consolidated balance sheet.

Decreased volumes across all businesses drove the decline in net sales during the three and six months ended June 30, 2009 compared to the same periods in 2008. The Emulsions and PVOH businesses experienced volume reductions due to decreased demand stemming from the global economic downturn. Declines in emulsions volumes were concentrated in North America and Europe, offset by a volume increase in Asia due to higher production at our Nanjing emulsions plant. PVOH volumes declined in North America and Europe due to continued weak demand. AT Plastics volumes declined due to the continued impact of the force majeure event at our Edmonton plant.

**Table of Contents**

Repairs to the plant were completed at the end of the second quarter 2009 and normal operations have resumed. Declines in price and unfavorable currency impacts also negatively impacted net sales during the period.

Operating profit decreased \$1 million for the three months ended June 30, 2009 compared to the same period in 2008 due to a decline in net sales which was partially offset by lower raw material and energy costs and reduced overall spending. Reduced spending is attributable to our fixed spending reduction efforts, restructuring efficiencies and favorable foreign currency impacts. Operating profit decreased \$8 million for the six months ended June 30, 2009 compared to the same period in 2008, as decreases in raw material and energy costs and reduced overall spending only partially offset lower net sales. Depreciation and amortization for the three and six months ended June 30, 2009 included accelerated amortization of \$3 million related to the AT Plastics trade name to be discontinued August 1, 2009.

**Acetyl Intermediates**

	Three Months Ended June 30,			Six Months Ended June 30,		Change in \$
	2009	2008	Change in \$ (unaudited)	2009	2008	
	(In \$ millions, except for percentages)					
Net sales	622	1,067	(445)	1,194	2,163	(969)
Net sales variance						
<i>Volume</i>	(11)%			(15)%		
<i>Price</i>	(28)%			(27)%		
<i>Currency</i>	(3)%			(3)%		
<i>Other</i>						
Other (charges) gains, net		(2)	2	(1)	(9)	8
Operating profit	40	148	(108)	52	325	(273)
Operating margin	6.4%	13.9%		4.4%	15.0%	
Earnings (loss) from continuing operations before tax	44	181	(137)	60	387	(327)
Depreciation and amortization	32	34	(2)	59	66	(7)

Our Acetyl Intermediates segment produces and supplies acetyl products, including acetic acid, VAM, acetic anhydride and acetate esters. These products are generally used as starting materials for colorants, paints, adhesives, coatings, textiles, medicines and more. Other chemicals produced in this segment are organic solvents and intermediates for pharmaceutical, agricultural and chemical products.

Acetyl Intermediates net sales declined by 42% and 45% during the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008 due to lower prices across all regions, lower volumes and unfavorable currency impacts. Lower volume was driven by a reduction in underlying demand compared to the same periods in 2008, particularly in Europe and in the Americas. Slowly improving demand in Asia drove volumes to be flat compared to the same periods in 2008. Lower industry utilization of acetyl intermediates products in Europe and the Americas coupled with lower raw material and energy prices, drove a reduction in selling prices in these regions during the period. Selling prices declined during the period as our formula-based pricing arrangements for VAM in the US were negatively impacted by lower raw material costs.

Operating profit declined \$108 million and \$273 million for the three and six months ended June 30, 2009, respectively, compared to the same period in 2008, primarily as a result of lower volume and prices, offset partially by lower raw material and energy prices, reduced spending due to the shutdown of our Pampa, Texas facility and other reductions in spending. Depreciation and amortization expense declined primarily as a result of the long-lived asset impairment losses recognized in the fourth quarter of 2008 related to our acetic acid and VAM production facility in Pardies, France, the closure of our VAM production unit in Cangrejera, Mexico in February 2009, coupled with lower depreciation resulting from the shutdown of our Pampa, Texas facility. Other charges of \$2 million and \$9 million during the three and six months ended June 30, 2008, respectively, were primarily related to the planned

## **Table of Contents**

shutdown of our Pampa, Texas facility. Other charges during the six months ended June 30, 2009 consists of \$6 million of insurance recoveries in satisfaction of claims we made related to the unplanned outage of our Clear Lake, Texas acetic acid facility during 2007, offset by charges related to the shutdown of our Cangrejera, Mexico facility and the alignment of staffing levels with our view of the current economic environment.

Earnings from continuing operations before tax declined \$137 million and \$327 million for the three and six months ended June 30, 2009, respectively, compared to the same period in 2008, due to lower operating profit and dividend income from our cost investment. Dividend income from our cost investment, Ibn Sina, declined \$27 million and \$50 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008 as a result of lower earnings from declining margins for methanol and MTBE.

On July 8, 2009, we announced that our wholly-owned French subsidiary, Acetex Chimie, completed the consultation procedure with the workers council on its Project of Closure and social plan related to our Pardies, France facility pursuant to which the we announced our formal intent to cease all manufacturing operations there and its associated activities. We have agreed with the workers council on a set of measures of assistance aimed at minimizing the effects of the plant's closing on the Pardies workforce, including training, outplacement, and severance.

### ***Other Activities***

Other Activities primarily consists of corporate center costs, including financing and administrative activities, and our captive insurance companies.

The operating loss for Other Activities decreased \$8 million and \$6 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008. The decrease in operating loss is primarily due to favorable currency impacts and reduced spending, partially offset by higher elimination charges for intercompany transactions.

The loss from continuing operations before tax decreased \$13 million and \$23 million for the three and six months ended June 30, 2009, respectively, compared to the same periods in 2008. The decrease is primarily due to reduced interest expense resulting from lower interest rates on our senior credit facilities during the period, favorable currency impacts and lower operating loss.

### **Liquidity and Capital Resources**

Our primary source of liquidity is cash generated from operations, available cash and cash equivalents and dividends from our portfolio of strategic investments. In addition, we have \$139 million available for borrowing under our credit-linked revolving facility and \$600 million available under our revolving credit facility to assist, if required, in meeting our working capital needs and other contractual obligations.

While our contractual obligations, commitments and debt service requirements over the next several years are significant, we continue to believe we will have available resources to meet our liquidity requirements, including debt service, for the remainder of 2009. If our cash flow from operations is insufficient to fund our debt service and other obligations, we may be required to use other means available to us such as increasing our borrowings, reducing or delaying capital expenditures, seeking additional capital or seeking to restructure or refinance our indebtedness. There can be no assurance, however, that we will continue to generate cash flows at or above current levels or that we will be able to maintain our ability to borrow under our revolving credit facilities.

As a result of the Project of Closure for our Pardies, France facility, we expect to record exit costs of \$90 million to \$100 million, primarily in the second half of 2009. We expect that substantially all of the exit costs (except for

accelerated depreciation of fixed assets) will result in future cash expenditures over a two-year period. See also the Acetyl Intermediates section of the MD&A.

On a stand-alone basis, Celanese Corporation has no material assets other than the stock of its subsidiaries and no independent external operations of its own. As such, Celanese Corporation generally will depend on the cash flow of its subsidiaries to meet its obligations under its preferred stock, Series A common stock and the senior credit agreement.

**Table of Contents**

***Cash Flows***

Cash and cash equivalents as of June 30, 2009 were \$1,145 million, which was an increase of \$469 million from December 31, 2008.

***Net Cash Provided by Operating Activities***

Cash flow from operations decreased \$47 million during the six months ended June 30, 2009 as compared to the same period in 2008. The decrease in operating profit of \$325 million was mostly offset by improvements in trade working capital.

***Net Cash Provided by (Used in) Investing Activities***

Net cash from investing activities increased from a cash outflow of \$33 million for the six months ended June 30, 2008 to a cash inflow of \$183 million for the same period in 2009. The increase is primarily due to receipt of proceeds of \$412 million compared to \$311 million for the same period in 2008 related to the Ticona Kelsterbach plant relocation. Fewer capital expenditures and less cash spent on the purchase of marketable securities more than offset the decrease in cash received from the sale of marketable securities. Cash spent on the Ticona Kelsterbach plant relocation of \$147 million was \$85 million higher than the same period in 2008.

Our cash outflow for capital expenditures was \$96 million and \$136 million for the six months ended June 30, 2009 and 2008, respectively. Capital expenditures were primarily related to major replacements of equipment, capacity expansions, major investments to reduce future operating costs, and environmental and health and safety initiatives. Capital expenditures are expected to be approximately \$185 million for 2009, excluding amounts related to the relocation of our Ticona plant in Kelsterbach. Cash outflows for capital expenditures for our Ticona plant in Kelsterbach are expected to range from \$350 million to \$370 million during 2009. Refer to the Ticona Kelsterbach Plant Relocation discussion in the Advanced Engineered Materials section of the MD&A for more detail.

***Net Cash Used in Financing Activities***

Net cash used in financing activities decreased from a cash outflow of \$183 million for the six months ended June 30, 2008 to a cash outflow of \$59 million for the same period in 2009. The \$124 million decrease primarily relates to the decrease in cash spent to repurchase shares during the six months ended June 30, 2009 as compared to 2008.

***Debt and Capital***

On July 2, 2009, we declared a cash dividend of \$0.265625 per share on our 4.25% convertible perpetual preferred stock amounting to \$3 million and a cash dividend of \$0.04 per share on our Series A common stock amounting to \$6 million. Both cash dividends are for the period from May 1, 2009 to July 31, 2009 and will be paid on August 3, 2009 to holders of record as of July 15, 2009.

In February 2008, our Board of Directors authorized the repurchase of up to \$400 million of our Series A common stock. This authorization was increased to \$500 million in October 2008. The authorization gives management discretion in determining the conditions under which shares may be repurchased. This repurchase program does not have an expiration date. As of June 30, 2009, we have purchased 9,763,200 shares of our Series A common stock at an average purchase price of \$38.68 per share for a total of \$378 million pursuant to this authorization. For the six months ended June 30, 2009, no shares of our Series A common stock were repurchased.

## Edgar Filing: Celanese CORP - Form 10-Q

As of June 30, 2009, we had total debt of \$3,492 million compared to \$3,533 million as of December 31, 2008. We were in compliance with all of the covenants related to our debt agreements as of June 30, 2009.

Our senior credit agreement consists of \$2,280 million of US dollar-denominated and 400 million of Euro-denominated term loans due 2014, a \$600 million revolving credit facility terminating in 2013 and a \$228 million credit-linked revolving facility terminating in 2014. Borrowings under the senior credit agreement bear interest at a variable interest rate based on LIBOR (for US dollars) or EURIBOR (for Euros), as applicable, or, for US dollar-denominated loans under certain circumstances, a base rate, in each case plus an applicable margin. The applicable

**Table of Contents**

margin for the term loans and any loans under the credit-linked revolving facility is 1.75%, subject to potential reductions as defined in the senior credit agreement. As of June 30, 2009, the applicable margin was 1.75%. The term loans under the senior credit agreement are subject to amortization at 1% of the initial principal amount per annum, payable quarterly. The remaining principal amount of the term loans is due on April 2, 2014.

As of June 30, 2009, there were \$89 million of letters of credit issued under the credit-linked revolving facility and \$139 million remained available for borrowing. As of June 30, 2009, there were no outstanding borrowings or letters of credit issued under the revolving credit facility.

On June 30, 2009, we entered into an amendment to the senior credit agreement. The amendment reduced the amount available under the revolving credit portion of the senior credit agreement from \$650 million to \$600 million and increased the first lien senior secured leverage ratio covenant that is applicable when any amount is outstanding under the revolving credit portion of the senior credit agreement. Prior to giving effect to the amendment, the maximum first lien senior secured leverage ratio was 3.90 to 1.00. As amended, the maximum senior secured leverage ratio for the following trailing four-quarter periods is as follows:

	<b>First Lien Senior Secured Leverage Ratio</b>
June 30, 2009	4.75 to 1.00
September 30, 2009	5.75 to 1.00
December 31, 2009	5.25 to 1.00
March 31, 2010	4.75 to 1.00
June 30, 2010	4.25 to 1.00
September 30, 2010	4.25 to 1.00
December 31, 2010 and thereafter	3.90 to 1.00

As a condition to borrowing funds or requesting that letters of credit be issued under the revolving credit facility, our first lien senior secured leverage ratio (as calculated as of the last day of the most recent fiscal quarter for which financial statements have been delivered under the revolving facility) cannot exceed a certain threshold as specified above. The first lien senior secured leverage ratio is calculated as the ratio of consolidated first lien senior secured debt to earnings before interest, taxes, depreciation and amortization, subject to adjustment identified in the credit agreement.

Based on the estimated first lien senior secured leverage ratio for the trailing four quarters at June 30, 2009, our borrowing capacity under the revolving credit facility is \$600 million. Further, our first lien senior secured leverage ratio must be maintained at or below that threshold while any amounts are outstanding under the revolving credit facility. As of the quarter ended June 30, 2009, we estimate our first lien senior secured leverage ratio to be 3.80 to 1.00 (which would be 4.59 to 1.00 were the revolving credit facility fully drawn). The maximum first lien senior secured leverage ratio under the revolving credit facility for such quarter is 4.75 to 1.00. Our availability in future periods will be based on the first lien senior secured leverage ratio applicable to the future periods.

Our senior credit agreement also contains a number of restrictions on certain of our subsidiaries, including, but not limited to, restrictions on their ability to incur indebtedness; grant liens on assets; merge, consolidate, or sell assets; pay dividends or make other restricted payments; make investments; prepay or modify certain indebtedness; engage in transactions with affiliates; enter into sale-leaseback transactions or hedge transactions; or engage in other businesses. The senior credit agreement also contains a number of affirmative covenants and events of default, including a cross



default to other debt of certain of our subsidiaries in an aggregate amount equal to more than \$40 million and the occurrence of a change of control. Failure to comply with these covenants, or the occurrence of any other event of default, could result in acceleration of the loans and other financial obligations under our senior credit agreement.

*Contractual Obligations*

There have been no material revisions to our contractual obligations as filed in our 2008 Form 10-K.

## **Table of Contents**

### ***Domination Agreement***

The domination and profit and loss transfer agreement (the *Domination Agreement*) was approved at the Celanese GmbH, formerly known as Celanese AG, extraordinary shareholders meeting on July 31, 2004. The *Domination Agreement* between Celanese GmbH and the Purchaser became effective on October 1, 2004 and cannot be terminated by the Purchaser in the ordinary course of business until September 30, 2009. Our subsidiaries, Celanese International Holdings Luxembourg S.à.r.l. (*CIH*), formerly Celanese Caylux Holdings Luxembourg S.C.A., and Celanese US, have each agreed to provide the Purchaser with financing to strengthen the Purchaser's ability to fulfill its obligations under, or in connection with, the *Domination Agreement* and to ensure that the Purchaser will perform all of its obligations under, or in connection with, the *Domination Agreement* when such obligations become due, including, without limitation, the obligation to compensate Celanese GmbH for any statutory annual loss incurred by Celanese GmbH during the term of the *Domination Agreement*. If *CIH* and/or Celanese US are obligated to make payments under such guarantees or other security to the Purchaser, we may not have sufficient funds for payments on our indebtedness when due. We have not had to compensate Celanese GmbH for an annual loss for any period during which the *Domination Agreement* has been in effect.

### **Off-Balance Sheet Arrangements**

We have not entered into any material off-balance sheet arrangements.

### **Critical Accounting Policies and Estimates**

Our consolidated financial statements are based on the selection and application of significant accounting policies. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues, expenses and allocated charges during the reporting period. Actual results could differ from those estimates. However, we are not currently aware of any reasonably likely events or circumstances that would result in materially different results.

We describe our significant accounting policies in Note 2, Summary of Accounting Policies, of the Notes to Consolidated Financial Statements included in our 2008 Form 10-K. We discuss our critical accounting policies and estimates in MD&A in our 2008 Form 10-K.

There have been no material revisions to the critical accounting policies as filed in our 2008 Form 10-K.

### **Recent Accounting Pronouncements**

See Notes 2 and 14 of the accompanying unaudited interim consolidated financial statements included in this Form 10-Q for a discussion of recent accounting pronouncements.

### **Item 3. *Quantitative and Qualitative Disclosures about Market Risk***

Market risk for our Company has not changed materially from the foreign exchange, interest rate and commodity risks disclosed in Item 7A in our 2008 Form 10-K.

### **Item 4. *Controls and Procedures***

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective.

**Changes in Internal Control Over Financial Reporting**

None.

**Table of Contents****PART II OTHER INFORMATION****Item 1. *Legal Proceedings***

We are involved in a number of legal proceedings, lawsuits and claims incidental to the normal conduct of our business, relating to such matters as product liability, antitrust, past waste disposal practices and release of chemicals into the environment. While it is impossible at this time to determine with certainty the ultimate outcome of these proceedings, lawsuits and claims, we believe, based on the advice of legal counsel, that adequate provisions have been made and that the ultimate outcomes will not have a material adverse effect on our financial position, but may have a material adverse effect on our results of operations or cash flows in any given accounting period. See also Note 12 to the unaudited interim consolidated financial statements for a discussion of legal proceedings.

There have been no significant developments in the Legal Proceedings described in our 2008 Form 10-K other than those disclosed in Note 12 to the unaudited interim consolidated financial statements.

**Item 1A. *Risk Factors***

There have been no material revisions to the Risk factors as filed in our 2008 Form 10-K.

**Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds***

There were no equity securities of the Company sold by the Company during the three months ended June 30, 2009 that were not registered under the Securities Act of 1933.

The table below sets forth information regarding repurchases of our Series A common stock during the three months ended June 30, 2009:

<b>Period</b>	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Program<sup>(2)</sup></b>	<b>Approximate Dollar Value of Shares Remaining that may be Purchased Under the Program</b>
April 1-30, 2009				\$ 122,300,000
May 1-31, 2009				\$ 122,300,000
June 1-30, 2009 <sup>(1)</sup>	3,909	\$ 21.37		\$ 122,300,000

<sup>(1)</sup> Relates to shares employees have elected to have withheld to cover their minimum withholding requirements for personal income taxes related to the vesting of restricted stock units.

<sup>(2)</sup> No shares were purchased during the three months ended June 30, 2009 under our previously announced stock purchase plan.

**Item 3. *Defaults Upon Senior Securities***

None.

**Item 4. *Submission of Matters to a Vote of Security Holders***

We held our annual meeting of shareholders on April 23, 2009. During this meeting, our shareholders were asked to consider and vote upon four proposals: 1) to elect three Class II Directors to our Board of Directors to serve for a term which expires at the annual meeting of shareholders in 2012 or until their successors are duly elected and qualified, 2) to ratify the appointment of our independent registered public accounting firm, 3) to approve the 2009 Global Incentive Plan and 4) to approve the 2009 Employee Stock Purchase Plan. Mark C. Rohr, Farah M. Walters and David N. Weidman continue to serve as Class III Directors, whose terms expire at the annual meeting of shareholders in 2010, and Martin G. McGuinn, Daniel S. Sanders and John K. Wulff continue to serve as Class I Directors, whose terms expire at the annual meeting of shareholders in 2011, or until their successors are duly elected and qualified.

**Table of Contents**

On the record date of March 2, 2009, there were 143,507,870 shares of Series A common stock issued and outstanding and entitled to be voted at the annual meeting, if represented. For each proposal, the results of the shareholder voting were as follows:

	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>
1. Election of the director nominees to serve in Class II, for a term which expires at the Annual Meeting of Shareholders in 2012, or until their successors are duly elected and qualified, as follows:			
James E. Barlett	104,681,041	19,121,561	32,244
David F. Hoffmeister	104,651,176	19,152,126	31,545
Paul H. O'Neill	102,971,047	20,823,780	40,020
	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>
2. Ratification of appointment of KPMG LLP as our independent registered public accounting firm	123,112,907	635,237	86,702
	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>
3. Approval of the 2009 Global Incentive Plan	91,332,780	24,181,239	57,220
	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>
4. Approval of the 2009 Employee Stock Purchase Plan	94,072,400	21,469,752	29,087

**Item 5. Other Information**

None.

**Item 6. Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
3.1	Second Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on January 28, 2005).
3.2	Third Amended and Restated By-laws, effective as of October 23, 2008 (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on October 29, 2008).
3.3	Certificate of Designations of 4.25% Convertible Perpetual Preferred Stock (Incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on January 28, 2005).
10.1	First Amendment to Credit Agreement (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on July 1, 2009).

Edgar Filing: Celanese CORP - Form 10-Q

- 10.2 Celanese Corporation 2009 Global Incentive Plan (Incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-8 filed on April 23, 2009).
- 10.3 Celanese Corporation 2009 Employee Stock Purchase Program (Incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-8 filed on April 23, 2009).
- 10.4 Amendment Number One to Celanese Corporation Deferred Compensation Plan (Incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-8 filed on April 23, 2009).
- 10.5 Form of Time-Vesting Restricted Stock Unit Award Agreement (filed herewith).
- 10.6 Form of Performance-Vesting Restricted Stock Unit Award Agreement together with a schedule identifying substantially identical agreements between the Company and each of its executive officers identified thereon (filed herewith).
- 10.7 Form of Nonqualified Stock Option Award Agreement together with a schedule identifying substantially identical agreements between the Company and each of its executive officers identified thereon (filed herewith).

**Table of Contents**

<b>Exhibit Number</b>	<b>Description</b>
10.8	Form of Long-Term Incentive Cash Award Agreement together with a schedule identifying substantially identical agreements between the Company and each of its executive officers identified thereon (filed herewith).
10.9	Restated Agreement and General Release, dated June 3, 2009, between the Company and Miguel A. Desdin (filed herewith).
10.10	Time-Vesting Restricted Stock Unit Award Agreement, dated April 23, 2009, between the Company and Gjon N. Nivica, Jr. (filed herewith).
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

*PLEASE NOTE:* It is inappropriate for readers to assume the accuracy of, or rely upon any covenants, representations or warranties that may be contained in agreements or other documents filed as Exhibits to, or incorporated by reference in, this Quarterly Report. Any such covenants, representations or warranties may have been qualified or superseded by disclosures contained in separate schedules or exhibits not filed with or incorporated by reference in this Quarterly Report, may reflect the parties' negotiated risk allocation in the particular transaction, may be qualified by materiality standards that differ from those applicable for securities law purposes, and may not be true as of the date of this Quarterly Report or any other date and may be subject to waivers by any or all of the parties. Where exhibits and schedules to agreements filed or incorporated by reference as Exhibits hereto are not included in these exhibits, such exhibits and schedules to agreements are not included or incorporated by reference herein.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CELANESE CORPORATION

Name: David N. Weidman  
By: /s/ David N. Weidman  
Title: Chairman of the Board of Directors and Chief Executive Officer

Date: July 29, 2009

Name: Steven M. Sterin  
By: /s/ Steven M. Sterin  
Title: Senior Vice President and Chief Financial Officer

Date: July 29, 2009